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Abstract. In dose-finding trials, due to staggered enrollment, it might be de-
sirable to make dose assignment decisions in real-time in the presence of pending
toxicity outcomes, for example, when patient accrual is fast or the dose-limiting tox-
icity is late-onset. Patients’ time-to-event information may be utilized to facilitate
such decisions. We propose a unified statistical framework for time-to-event model-
ing in dose-finding trials, which leads to two classes of time-to-event designs: TITE
deigns and POD designs. TITE designs are based on inference on toxicity proba-
bilities, while POD designs are based on inference on dose-finding decisions. These
two classes of designs contain existing designs as special cases and also give rise to
new designs. We discuss and study theoretical properties of these designs, including
large-sample convergence properties, coherence principles, and the underlying de-
cision rules. To facilitate the use of time-to-event designs in practice, we introduce
efficient computational algorithms and review common practical considerations,
such as safety rules and suspension rules. Finally, the operating characteristics of
several designs are evaluated and compared through computer simulations.
1. Introduction
The goal of dose-finding trials is to find the maximum tolerated dose (MTD), the
highest dose with toxicity probability close to or lower than a pre-specified target rate
pT. The type of toxicity is usually severe, like organ failure, and is called dose-limiting
toxicity (DLT). The premise behind dose-finding trials is that both the toxicity and
efficacy of a treatment monotonically increase with the dose level. A dose level that
is too low can not provide needed efficacy, e.g. anti-tumor activity, while a dose
level that is too high might have severe toxicity. Therefore, it is crucial to find
an appropriate dose that has the highest possible efficacy while maintains tolerable
toxicity. Usually, a grid of discrete dose levels are investigated, and cohorts of patients
are sequentially enrolled and adaptively treated at dose levels based on the previously
observed data. The trial objectives include the identification of the MTD and the
estimation of the dose-toxicity curve, as well as maximizing the chance of treating
patients at safe and efficacious doses.
Key words and phrases. Clinical trial design; Late-onset toxicity; Maximum tolerated dose; Miss-
ing data; Survival analysis.
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The evaluation of DLT is conducted by following patients post-treatment within
a time window. During the time window, DLT events are recorded, if any. If a
patient does not experience any DLT during the follow-up window, the patient is
declared having no DLT. Most existing designs require the DLT evaluation of all
the previously enrolled cohorts to be completed before they can make a treatment
assignment for the next cohort. Consequently, we refer to this type of designs as
complete-data designs. Examples of complete-data designs include the 3+3 design
(Storer, 1989), continual reassessment method (CRM, O’Quigley et al., 1990; Good-
man et al., 1995; Shen and O’Quigley, 1996; O’Quigley and Shen, 1996), escalation
with overdose control (EWOC, Babb et al., 1998), cumulative cohort design (CCD,
Ivanova et al., 2007), Bayesian logistic regression model (BLRM, Neuenschwander
et al., 2008), modified toxicity probability interval design (mTPI, Ji et al., 2010; Ji
and Wang, 2013), Bayesian optimal interval design (BOIN, Liu and Yuan, 2015; Yuan
et al., 2016), mTPI-2 design (Guo et al., 2017), keyboard design (Yan et al., 2017),
semiparametric dose finding method (SPM, Clertant and O’Quigley, 2017; Clertant
and O’Quigley, 2019) and i3+3 design (Liu et al., 2020), among many others. For
therapies of which the toxicity is acute and can be ascertained in early cycles, such
as cytotoxic therapies, waiting for the DLT evaluation of previous patients may not
be a concern, as the DLT assessment window can be short. However, for therapies
that usually have late-onset toxicity, such as immunotherapies (Weber et al., 2015;
Kanjanapan et al., 2019), it is more sensible to use a relatively long assessment win-
dow. This may cause difficulty for these designs to operate, since patient enrollment
needs to be frequently suspended until the previous patients have finished their as-
sessment. The same difficulty arises when patient accrual is fast compared to the
length of the assessment window. For example, in Figure 1.1(a), while waiting for
the DLT outcomes of the first 3 patients, the trial needs to be suspended, and 3
eligible patients have to be turned away. Trial suspension is undesirable in practice
for two reasons. First, trial duration is prolonged, which delays scientific research
and drug development. Second, subsequent patients that are available for enrollment
need to be turned away, which results in a delay in their cancer care. Many patients
participating in the trial do not have alternative choices for treatment, and the trial
may be their last treatment option. Their diseases may also be in rapid deterioration,
thus they are in need of immediate treatment.
A UNIFIED FRAMEWORK FOR TIME-TO-EVENT DOSE-FINDING DESIGNS 3
Pa
tie
nt
Time (in days)
0 7    16   22    30    38     47   55
×
35
21
44
5
4
3
2
1
Patient accrual
Patient turned away
No DLT within assessment window
DLT×
SUSPEND
Dose
d-1
d-1
d
d
d
Pa
tie
nt
Time (in days)
0 7    16   22    30    38 
×
35
21
44
6
5
4
3
2
1
Dose
d-1
d-1
d-1
d
d
d
50
(a) Complete-data designs (b) Time-to-event designs
Figure 1.1. Illustration of complete-data designs and time-to-event
designs. Suppose the target DLT rate is 0.17, the length of the DLT
assessment window is 28 days, and patients are enrolled in cohorts of 3.
Using complete-data designs (a), the trial needs to be suspended while
waiting for the DLT outcomes of the first 3 patients. Using time-to-
event designs (b), the suspension may be avoided.
To address these practical concerns, several designs have been proposed to allow for
consecutive patient accrual even if some enrolled patients are still pending for DLT
assessment. These include the time-to-event CRM (TITE-CRM, Cheung and Chap-
pell, 2000; Normolle and Lawrence, 2006), rolling six design (R6, Skolnik et al., 2008),
expectation-maximization CRM (EM-CRM, Yuan and Yin, 2011), data augmenta-
tion CRM (DA-CRM, Liu et al., 2013), time-to-event BOIN design (TITE-BOIN,
Yuan et al., 2018), time-to-event keyboard design (TITE-keyboard, Lin and Yuan,
2019), rolling TPI design (R-TPI, Guo et al., 2019) and probability-of-decision TPI
design (POD-TPI, Zhou et al., 2020). Except for R6 and R-TPI, these designs uti-
lize time-to-event information to make treatment assignments thus are referred to
as time-to-event designs. As an example, in Figure 1.1(b), when the 4th patient is
available for enrollment, patients 2 and 3 are still being followed without definitive
outcomes. Based on the DLT outcome of patient 1, time-to-DLT information of pa-
tient 1 and follow-up time information of patients 2 and 3, a time-to-event design may
enroll the patient and de-escalate the dose level, which avoids the trial suspension.
In this article, we aim to propose a unified statistical framework for time-to-event
modeling in dose-finding trials. See Figure 1.2 for a summary. The key component is
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the construction of the likelihood function with time-to-event data, and the primary
interest is inference on toxicity probabilities. Specifically, two equivalent modeling
approaches can be taken for the likelihood construction. The statistical framework
gives rise to two classes of time-to-event designs, which contain the existing time-to-
event designs as special cases and also lead to new time-to-event designs. The first
class of time-to-event designs, called TITE designs, make dose-finding decisions based
on inference on toxicity probabilities. The second class of time-to-event designs, called
POD (probability of decision) designs, is a new type of designs that directly make
inference on dose-finding decisions when DLT outcomes may be pending. The POD
designs directly reflect the confidence of possible decisions and offer the investigators
and regulators a way to properly assess and control the chance of making incompatible
decisions when not all patients have been completely followed. As a result, we argue
that the POD designs might be more suitable for practical applications.
Time-to-
event data
Survival 
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Survival + 
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modeling
Inference 
on toxicity 
probability
Inference on 
decision
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designs
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Figure 1.2. Illustration of a statistical framework for time-to-event
modeling in dose-finding trials and two classes of time-to-event designs.
Along with the statistical framework, we introduce several computational algo-
rithms to facilitate the use of time-to-event designs in practice. We discuss and
study theoretical properties of time-to-event designs, such as large-sample conver-
gence properties, coherence principles and the underlying decision rules, with a focus
on interval-based nonparametric designs. We also review practical considerations of
time-to-event designs, which are important in the execution of clinical trials. Usually,
ad-hoc rules need to be imposed to ensure that the designs satisfy safety concerns
and ethical constraints. Lastly, we examine finite-sample operating characteristics of
some designs through computer simulations.
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The remainder of the paper is structured as follows. In Section 2, we give a brief
review of complete-data designs. In Section 3, we describe a framework for time-to-
event modeling in dose-finding trials. In Section 4, we introduce the two classes of
time-to-event designs, including the TITE and POD designs. In Section 5, we study
theoretical properties of time-to-event designs. In Section 6, we discuss practical
considerations. We assess the operating characteristics of several existing and newly
proposed dose-finding designs via simulation studies in Section 7. Finally, we con-
clude with a discussion in Section 8. Technical details, including the computational
algorithms and proof of the theoretical results, are provided in the Appendix.
2. Review of Complete-Data Designs
We start with a brief review of complete-data designs. At a certain moment in a
dose-finding trial, suppose N patients have been treated, and the (N + 1)th patient
is eligible for enrollment. Let Zi ∈ {1, . . . , D} denote the dose assigned to patient i,
where D is the number of available doses in the trial. Each patient is supposed to be
followed for a fixed period of time W , and we use Yi = 1 or 0 to represent whether
or not patient i experiences DLT within the time window, respectively. For example,
in many oncology trials, W = 28 days. The conditional distribution of Yi given Zi is
commonly modeled with a Bernoulli distribution,
Pr(Yi = y | Zi = z, pz) = pyz(1− pz)1−y, y ∈ {0, 1}.(2.1)
Here, pz is the probability of DLT at dose z within the assessment window. A widely
recognized assumption is that the DLT probability is monotone with the dose level,
i.e. p1 ≤ p2 ≤ · · · ≤ pD.
Suppose Yi’s are fully observed for the first N patients, and denote by H∗N =
{(Yi, Zi) : i ≤ N} the previous history of observations. A complete-data design A∗
can be viewed as a function of H∗N , which prescribes a dose A∗(H∗N) for the new
patient through two steps: (1) making inference about pz’s, and (2) translating such
inference to a dose-finding decision. Inference on pz’s can be based on the likelihood,
L(p | H∗N) =
N∏
i=1
pyizi(1− pzi)1−yi ,(2.2)
where y = (y1, . . . , yN) and z = (z1, . . . , zN) are the observed outcomes and dose
assignments for the N patients, respectively, and p = (p1, . . . , pD) is the vector
of toxicity probabilities. As mentioned in Section 1, there is a rich literature on
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complete-data dose-finding designs. We provide a brief review of several designs in
Appendix A.
For the following discussion, it is helpful to categorize the existing complete-data
designs into several classes. First, we can categorize the designs according to how they
make inference about p. A parametric design (e.g., CRM and BLRM) models the
toxicity probabilities with a parametric curve pz = φ(z,α), which is monotonically
increasing in z. A nonparametric design (e.g., BOIN and mTPI-2) does not make
parametric assumptions for estimating p. A semiparametric design (e.g., SPM) does
not make parametric assumptions about p but imposes some constraint on p to
ensure its (partial) ordering. Second, we can also categorize the designs based on
how they translate inference on p to a dose assignment decision. Generally, a design
starts at a low dose. At each subsequent step, a point-based design (e.g., CRM)
allocates the next cohort to d∗ = arg minz |pˆz − pT|, where pˆz is a point estimate
of pz (e.g., MLE or posterior mean) based on (2.2). On the other hand, suppose
the currently-administered dose is d, and 1 > 0 and 2 > 0 are pre-determined
constants. Interval-based designs make dose-finding decisions based on the interval
IE = [pT − 1, pT + 2]. One class of interval-based designs (e.g., CCD and BOIN)
make stay (at d), escalation (to d + 1) or de-escalation (to d − 1) decisions based
on whether pˆd is within, below or above IE, respectively. Another class of interval-
based designs (e.g., mTPI-2 and keyboard) consider a partition of the [0, 1] interval
into sub-intervals (from left to right) {IU0 , . . . , IUK1}, IE and {IO0 , . . . , IOK2}, where
IE = [pT − 1, pT + 2] is the only sub-interval that contains pT. The dose-finding
decision is stay (at d), escalation (to d + 1) or de-escalation (to d − 1) if arg maxj
Pr(pd ∈ Ij | H∗N) equals E, belongs to {U0, . . . ,UK1} or belongs to {O0, . . . ,OK2},
respectively. Here, Pr(pd ∈ Ij | H∗N) is the posterior probability of pd falling within
the interval Ij. Although the existing complete-data designs differ in many aspects,
they can be extended to time-to-event designs based on the same strategy, which will
be elaborated in the next sections.
3. Framework for Time-to-Event Modeling in Dose-Finding Trials
3.1. Setup. Since patients enter clinical trials sequentially at random time, it is often
the case that when a new patient is eligible for enrollment, some previously enrolled
patients are still being followed without DLT, thus their DLT outcomes Yi’s remain
unknown. As discussed in Section 1, even when some outcomes are pending, it is
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still desirable to enroll the patient and assign an appropriate dose. Complete-data
designs do not allow this, and time-to-event designs attempt to address this problem.
The key is to develop inference on p and a decision rule. With pending outcomes,
inference on p becomes less straightforward and ideally requires modeling time-to-
event data, because these data provide information regarding the likelihood of the
pending patients experiencing DLT in the future (Cheung and Chappell, 2000; Yuan
et al., 2018). For example, a patient followed for 21 days without DLT provides
different information from another followed for 2 days without DLT. Such difference
can be exploited for better inference and decision making.
Define trail time as the number of days since the enrollment of the first patient.
Let τ ∗i denote the trial time when patient i is enrolled. By definition, τ
∗
1 = 0. A
patient will be followed for a duration of W days. Call W the follow-up window.
We denote by (τ ∗i + Ti) the trial time when patient i experiences DLT. Note that
Ti can be greater than W in reality. At any trial time τ , patient i may or may
not have experienced DLT. If s/he has experienced DLT, then (τ ∗i + Ti) ≤ τ . If
s/he has not experienced DLT, s/he either is still being followed or has completed
W days of follow-up, but without experiencing DLT in either case, and we call the
patient is “censored”. At trial time τ , a patient i who is censored has a censoring
time Ui(τ) = min{max(τ − τ ∗i , 0),W}. Let Yi be the indicator of whether patient i
experiences DLT within the follow-up window W , i.e., Yi = 1(Ti ≤ W ). We do not
observe Ti at trial time τ if Ti > Ui(τ), but we always observe the follow-up time of
the patient, given by Vi = Ti∧Ui(τ). Similarly, we do not observe indicator Yi at trial
time τ if Ti > Ui(τ) and Ui(τ) < W , but we always know the current DLT status
of the patient, given by Y˜i = 1[Ti ≤ Ui(τ)]. For example, in Figure 1.1(b), we have
τ ∗1 = 0 and τ
∗
2 = 7 for patients 1 and 2, respectively. On day τ = 22 since trial start,
for patient 1, we have T1 = 21, U1 = 22, V1 = 21, and Y1 = Y˜1 = 1; for patient 2, we
have U2 = 15, V2 = 15, Y˜2 = 0, and T2 and Y2 are unknown. The available information
at study time τ can be summarized by H(τ) = {(Y˜i(τ), Vi(τ), Zi) : i ≤ N(τ)}, where
N(τ) is the total number of treated patients just prior to τ . A time-to-event design
A can be viewed as a function of H(τ). That is, if a new patient is enrolled at time
τ , the design would assign a dose A[H(τ)] for the patient.
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We introduce some more notation to facilitate the upcoming discussion. Denote
by
Bi(τ) =
0, if Y˜i(τ) = 0 and Vi(τ) < W ;1, if Y˜i(τ) = 1, or Y˜i(τ) = 0 and Vi(τ) = W.
In other words, Bi(τ) = 0 or 1 represents patient i’s DLT outcome Yi has not or
has been fully assessed, respectively. Therefore, Yi = Y˜i(τ) if Bi(τ) = 1. Following
the convention in the missing data literature, we use Yobs(τ) = {Yi : Bi(τ) = 1, i ≤
N(τ)} or Ymis(τ) = {Yi : Bi(τ) = 0, i ≤ N(τ)} to represent the sets of DLT out-
comes that have been observed or are pending at time τ , respectively. Lastly, let
Nz(τ) =
∑N(τ)
i=1 1(Zi = z) denote the number of patients that have been treated at
dose z just prior to τ . Among the Nz(τ) patients, let nz(τ), mz(τ) and rz(τ) denote
the number of patients having DLT, non-DLT and pending outcomes, respectively.
Mathematically, these can be written as nz(τ) =
∑N(τ)
i=1 1[Zi = z, Yi = 1, Bi(τ) = 1],
mz(τ) =
∑N(τ)
i=1 1[Zi = z, Yi = 0, Bi(τ) = 1], and rz(τ) =
∑N(τ)
i=1 1[Zi = z,Bi(τ) = 0].
In the next sections, we will describe how to use the observed data H(τ) to make
inference on p.
3.2. Modeling Time-to-Toxicity Data. In the first step, we specify a model for
the time-to-toxicity data. For the following discussion, patient index i is suppressed
from the subscript to simplify notation when no confusion is likely. Recall that
{Y = 1} is equivalent to {T ≤ W}. We still model Y with a Bernoulli distribution
as in Equation (2.1), which is equivalent to assuming Pr(T ≤ W | Z = z, pz) = pz.
Next, we generally write fT |Z(t | z,p, ξ) the probability density function (pdf) of
T at dose level Z = z, where ξ denotes additional and nuisance parameters that
characterize the distribution of T . For t ≤ W ,
fT |Z(t | z,p, ξ) = Pr(Y = 1 | Z = z,p, ξ) · fT |Z,Y (t | z, Y = 1,p, ξ)
= pz · fT |Z,Y (t | z, Y = 1, ξ).
The first equation is true since fT |Z,Y (t | z, Y = 0,p, ξ) = 0 for t ≤ W . The second
equation assumes that the conditional distribution fT |Z,Y (t | z, Y = 1,p, ξ) does not
depend on p. That is, given that a patient experiences DLT within the assessment
window at a dose z, when the patient experiences the DLT does not depend on
the toxicity probability pz of the dose. This assumption is implicitly made by all
existing methods (both complete-data designs and time-to-event designs). Note that
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if fT |Z,Y (t | z, Y = 1,p, ξ) does depend on p, it should be included in the complete
data likelihood (2.2) according to the likelihood principle.
To specify fT |Z(t | z,p, ξ), it suffices to specify fT |Z,Y (t | z, Y = 1, ξ), which can be
any probability density with support in (0,W ]. Examples of possible specifications of
fT |Z,Y (t | z, Y = 1, ξ) include a uniform distribution, a piecewise uniform distribution,
a discrete hazard model, a piecewise constant hazard model, and a rescaled beta
distribution. See Appendix B for details.
The survival function of T is given by
ST |Z(t | z,p, ξ) = Pr(T > t | Z = z,p, ξ) =
∫ ∞
t
fT |Z(v | z,p, ξ)dv.
The survival function must satisfy ST |Z(W | z,p, ξ) = 1−pz. This is important, since
pz only represents the probability of DLT within time window (0,W ]. For t < W ,
ST |Z(t | z,p, ξ) = 1− pz
∫ t
0
fT |Z,Y (v | z, Y = 1, ξ)dv , 1− pzρ(t | z, ξ),
where we denote by
ρ(t | z, ξ) =
∫ t
0
fT |Z,Y (v | z, Y = 1, ξ)dv.(3.1)
Remark 3.1. The function ρ(t | z, ξ) must satisfy: (1) ρ(t | z, ξ) ∈ [0, 1] for t ∈ (0,W ],
and (2) ρ(W | z, ξ) = 1. Also, by definition, ρ(t | z, ξ) is non-decreasing in t.
3.3. Survival Likelihood. The likelihood of p and ξ at time τ can be constructed
based on survival modeling by treating the unknown times-to-toxicities (i.e., {Ti :
Y˜i(τ) = 0, i ≤ N(τ)}) as censored observations. See, for example, Section 3.5 in
Klein and Moeschberger (2006). To simplify notation, we omit the time index τ
in the following discussion. For the patients with observed toxicities (Y˜i = 1), their
contributions to the likelihood are the pdfs of the times-to-toxicities. For the patients
without observed toxicities (Y˜i = 0), their times-to-toxicities are right censored, and
their contributions to the likelihood are the survival functions at the censoring times.
In particular,
L(p, ξ | H) =
N∏
i=1
[
fT |Z(vi | zi,p, ξ)1(y˜i=1)ST |Z(vi | zi,p, ξ)1(y˜i=0)
]
.
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The likelihood can be further written as
(3.2) L(p, ξ | H) =
N∏
i=1
{
p1(y˜i=1)zi fT |Z,Y (vi | zi, Y = 1, ξ)1(y˜i=1)×
[1− ρ(vi | zi, ξ)pzi ]1(y˜i=0)
}
.
Here, due to Remark 3.1, ρi , ρ(vi | zi, ξ) can be interpreted as the weight of
a patient who is still being followed within the assessment window. The likelihood
(3.2) can be considered as a weighted likelihood as in Cheung and Chappell (2000),
where a patient with a complete outcome (y˜i = 1, or y˜i = 0 and vi = W ) receives
full weight, and a patient with a pending outcome (y˜i = 0 and vi < W ) receives a
weight of ρi. The longer the follow-up time, the larger the weight. The last term
fT |Z,Y (vi | zi, Y = 1, ξ) is not related to p but provides information about the time-
to-toxicity.
From a Bayesian perspective, with the likelihood (3.2) and prior distributions pi0(p)
and pi0(ξ), inference on p and ξ is realized using the posterior distribution,
pi(p, ξ | H) ∝ pi0(p)pi0(ξ)L(p, ξ | H).
In general, the posterior is not available in closed form, and Monte Carlo simula-
tion is applied to approximate the posterior. We provide a simple computational
algorithm in Appendix C.1. From a frequentist perspective, the maximum like-
lihood estimate (MLE) pˆ can be used as an estimate for p. One can calculate
(pˆ, ξˆ) = arg maxp,ξ L(p, ξ | H) by taking partial derivatives of the log-likelihood
with respect to all the parameters or using other optimization techniques. Again, see
more details in Appendix C.1. In the CRM and BLRM designs, p is modeled by a
parametric curve, pz = φ(z,α), where α denotes unknown parameters. In such cases,
the likelihood (3.2) is re-parameterized with respect to α, and a prior distribution
pi0(α) would be specified for α (instead of p).
3.4. Augmented Likelihood with Missing Data. The likelihood of p and ξ can
be alternatively constructed based on modeling of missing data by treating the pend-
ing DLT outcomes (i.e., Ymis) as missing and augmenting the likelihood function
that incorporates the unknown Ymis as a vector of latent variables. Specifically, a
patient having an observed toxic outcome (Yi = 1 and Bi = 1) and a known DLT
time vi contributes pzifT |Z,Y (vi | zi, Y = 1, ξ) to the likelihood. A patient having
a latent toxic outcome (Yi = 1 and Bi = 0) and a follow-up time vi contributes
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pzi
∫W
vi
fT |Z,Y (t | zi, Y = 1, ξ)dt to the likelihood, because the DLT will occur in the
interval (vi,W ]. Finally, a patient with an observed or latent non-DLT outcome
(Yi = 0) contributes (1−pzi) to the likelihood. Therefore, using (3.1), the augmented
likelihood is given by
(3.3) L(p, ξ,ymis | H) =
N∏
i=1
{
p1(yi=1)zi (1− pzi)1(yi=0)×
fT |Z,Y (vi | zi, Y = 1, ξ)1(yi=1,bi=1) [1− ρ(vi | zi, ξ)]1(yi=1,bi=0)
}
.
Although the augmented likelihood involves additional parameters compared to the
survival likelihood, the following proposition shows inference under both approaches
is the same.
Proposition 3.1. The derived likelihood by marginalizing (3.3) over ymis is the same
as the survival likelihood (3.2) for p and ξ.
The proof is given in Appendix C.2. The augmented likelihood opens the door to
a set of flexible computational algorithms for making inference on p. For example,
the posterior distribution pi(p | H) can be simulated using the data augmentation
method (Tanner and Wong, 1987). The MLE of p can be calculated through the
expectation-maximization algorithm (Dempster et al., 1977). We elaborate these
methods in Appendix C.3. The inference involves the conditional probability,
Pr(Ymis,i = 1 | Zi = zi, Ti > vi,p, ξ)(3.4)
=
Pr(Ti > vi | Zi = zi, Ymis,i = 1, ξ) · Pr(Ymis,i = 1 | Zi = zi,p)∑
y∈{0,1} Pr(Ti > vi | Zi = zi, Ymis,i = y, ξ) · Pr(Ymis,i = y | Zi = zi,p)
=
[1− ρ(vi | zi, ξ)] · pzi
[1− ρ(vi | zi, ξ)] · pzi + (1− pzi)
.
That is, the probability of a pending patient experiencing DLT within the assessment
window given the patient is treated at dose zi and has been followed for vi units of
time.
4. Two Classes of Time-to-Event Designs
4.1. TITE Designs. In Section 3, we have proposed a statistical framework for time-
to-event modeling in dose-finding trials. Based on this framework and using each of
the complete-data designs (Section 2), one can easily generate a corresponding time-
to-event design. Following the literature, we call this class of designs TITE designs.
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Below, we illustrate this idea through reviewing five existing TITE designs: TITE-
CRM, EM-CRM, DA-CRM, TITE-BOIN and TITE-keyboard, and proposing three
new TITE designs: TITE-TPI, TITE-SPM and TITE-i3.
4.1.1. Existing TITE Designs.
TITE-CRM & EM-CRM & DA-CRM: The TITE-CRM design (Cheung and
Chappell, 2000) is a TITE extension of the CRM design. It assumes a dose-toxicity
curve pz = φ(z, α), such that φ monotonically increases with z, and α is an unknown
parameter. For example, a commonly used dose-toxicity curve is φ(z, α) = p
exp(α)
0z ,
where p0z’s are pre-specified constants (skeletons) satisfying p01 < · · · < p0D. The
likelihood (3.2) is re-parameterized with respect to α and becomes
L(α, ξ | H) =
N∏
i=1
{
φ(zi, α)
1(y˜i=1) [1− ρ(vi | zi, ξ)φ(zi, α)]1(y˜i=0)×
fT |Z,Y (vi | zi, Y = 1, ξ)1(y˜i=1)
}
.
By default, the conditional distribution of [T | Z, Y = 1] is modeled by a uniform
distribution, thus ρ(vi | zi, ξ) ≡ vi/W and fT |Z,Y (vi | zi, Y = 1, ξ) ≡ 1/W . Al-
ternatively, one can model [T | Z, Y = 1] with a piecewise-uniform distribution,
which can be calibrated to match the adaptive weighting scheme described in Che-
ung and Chappell (2000). Inference on p can be Bayesian or based on MLE. The
dose d∗ = arg minz |pˆz − pT| is recommended for the next patient, subject to some
practical safety restrictions (Goodman et al., 1995; Cheung, 2005). Here pˆz is an
appropriate point estimate of pz.
The EM-CRM (Yuan and Yin, 2011) and DA-CRM (Liu et al., 2013) are two alter-
native TITE extensions of the CRM design. They take the missing data modeling ap-
proach and consider the augmented likelihood (3.3). EM-CRM models [T | Z, Y = 1]
with a discrete hazard model and estimates p using the expectation-maximization
algorithm. It also has an additional layer of model averaging over different choices
of skeletons to improve its robustness. DA-CRM models [T | Z, Y = 1] with a piece-
wise constant hazard model and estimates p using the data augmentation method.
According to Proposition 3.1, TITE-CRM, EM-CRM and DA-CRM would yield iden-
tical inference if the same specification of fT |Z,Y (t | z, Y = 1, ξ) was used.
TITE BOIN: The TITE-BOIN design (Yuan et al., 2018) is a TITE extension of
the BOIN design. See Appendix A.2 for more details about BOIN. To maintain the
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transparent and simple decision rules in BOIN, TITE-BOIN uses single imputation,
substituting Ymis with their expected values yˆmis. Specifically, yˆmis,i = E(Ymis,i =
1 | Zi = zi, Ti > vi,p, ξ) = Pr(Ymis,i = 1 | Zi = zi, Ti > vi,p, ξ), given in (3.4).
A uniform distribution is assumed for [T | Z, Y = 1], thus ρ(vi | zi, ξ) ≡ vi/W .
The imputation involves the unknown parameter p, for which an estimate based on
an approximation procedure is plugged in. Finally, the decision rule of BOIN is
applied to the imputed dataset (yobs, yˆmis). We note that another way of extending
the BOIN design is to consider the BOIN hypothesis test (Appendix Equation A.1)
directly under the likelihood (3.2), although this would be more complicated than
the single imputation approach.
TITE-keyboard: The TITE-keyboard design (Lin and Yuan, 2019) is a TITE ex-
tension of the keyboard design. It considers a partition of the [0, 1] interval into
sub-intervals {IU0 , IU1 , . . . , IUK1}, IE and {IO0 , IO1 , . . . , IOK2}, such that all the sub-
intervals have the same length except for the intervals reaching the boundary of [0, 1].
Here, IE = [pT − 1, pT + 2] is the only sub-interval that contains pT, IUk ’s are on
the left of IE, and IOk ’s are on the right of IE. Except for the two boundary sub-
intervals (denoted by IU0 and IO0), the equal-length sub-intervals are referred to as
keys, and IE is referred to as the target key. By default, TITE-keyboard assumes
independent Beta(1, 1) priors on pz’s, pi0(pz) = 1[0,1]. Suppose the current dose is
d. With a model for [T | Z, Y = 1] and an additional prior pi0(ξ), the posterior
pi(pd, ξ | H) ∝ pi0(pd)pi0(ξ)L(p, ξ | H). Let j∗ = arg maxj Pr(pd ∈ Ij | H). The dose
assignment decision for the next patient follows the keyboard design. That is, to
escalate, stay or de-escalate, if j∗ belongs to {U1, . . . ,UK1}, equals E or belongs to
{O1, . . . ,OK2}, respectively.
4.1.2. New TITE Designs.
TITE-TPI: We propose the TITE-TPI design as a TITE extension of the mTPI-2
design. Similar to the keyboard design, mTPI-2 considers a partition of the [0, 1]
interval into equal-length sub-intervals. The sub-interval IE is referred to as the
equivalence interval, IUk ’s are referred to as underdosing intervals, and IOk ’s are
referred to as overdosing intervals. Let d denote the current dose level, and let model
Md = j represent {pd ∈ Ij}, j = U0, . . . ,UK1 ,E,O0, . . . ,OK2 . We consider the
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following hierarchical prior model for pd,
Pr(Md = j) = 1/(K1 +K2 + 3), for j = U0, . . . ,UK1 ,E,O0, . . . ,OK2 ;
pd | Md ∼ TBeta(1, 1; IMd),
where TBeta(·, ·; I) represents a truncated beta distribution restricted to interval
I. For TITE-TPI, with a model for [T | Z, Y = 1] and an additional prior pi0(ξ),
the posterior pi(Md, pd, ξ | H) ∝ pi0(Md)pi0(pd | Md)pi0(ξ)L(p, ξ | H). The dose
assignment decision for TITE-TPI follows the mTPI-2 design. That is, to escalate,
stay or de-escalate, if arg maxj Pr(Md = j | H) belongs to {U0, . . . ,UK1}, equals E
or belongs to {O0, . . . ,OK2}, respectively.
TITE-SPM: We propose the TITE-SPM design as a TITE extension of the SPM
design. The SPM directly models the the location of the MTD γ, γ ∈ {1, . . . , D}.
That is, {γ = d} means dose level d is the MTD. Conditional on γ, the support of pz
is restricted to
supp(pz) =

IU = [0, pT − 1), if z < γ;
IE = [pT − 1, pT + 2], if z = γ;
IO = (pT + 2, 1], if z > γ.
This restriction guarantees the partial ordering of the pz’s. The priors on γ and pz’s
can be specified as follows,
Pr(γ = z∗) = κz∗ ,
pz | γ ∼ TBeta(cθγz + 1, c(1− θγz ) + 1; Iγz ).
Here κz∗ , c and θ
γ
z are hyperparameters, and I
γ
z = IU, IE or IO for z < γ, z = γ
or z > γ, respectively. The hyperparameter θγz is the prior mode of pz if γ is the
assumed MTD, and is specified in a similar fashion as CRM. For TITE-SPM, with
a model for [T | Z, Y = 1] and an additional prior pi0(ξ), the posterior pi(γ,p, ξ |
H) ∝ pi0(γ)pi0(p | γ)pi0(ξ)L(p, ξ | H). The dose assignment decision for TITE-SPM
follows the SPM design. That is, to assign the dose γˆ = arg maxγ pi(γ | H) to the
next patient, subject to some safety restrictions.
TITE-i3: We propose the TITE-i3 design as a TITE extension of the i3+3 design.
The i3+3 design consists of a set of algorithmic decision rules, that is, model free.
Again, it considers a partition of the [0, 1] interval into IE, IU and IO. Suppose the
current dose is d. If nd/Nd ∈ IU, the decision is to escalate. If nd/Nd ∈ IE, the
decision is to stay. If nd/Nd ∈ IO, the decision is to stay when (nd − 1)/Nd ∈ IU and
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is to de-escalate otherwise. For TITE-i3, we replace nd in the i3+3 design with Ndpˆd,
where pˆd is the MLE under the likelihood (3.2). To maintain the simple algorithmic
rules in i3+3, we model [T | Z, Y = 1] with a uniform distribution, and the MLE is
easy to solve.
According to how a design makes inference about p and translates such inference
to a dose-finding decision, we can categorize the TITE designs in the same way as
the complete-data designs (Section 2). For example, TITE-CRM is a point-based
parametric TITE design, and TITE-BOIN, TITE-keyboard, TITE-TPI and TITE-i3
are interval-based nonparametric TITE designs.
4.2. POD Designs. Taking one step further of the TITE designs, one can directly
make inference on possible dose-finding decisions when some DLT outcomes are pend-
ing. This leads to a new class of POD (probability-of-decision) designs. We discuss
the details next.
As mentioned in Section 2, the dose assignment decision for any complete-data
design can be written as a deterministic function of the previous (complete) DLT out-
comes y and dose assignments z, denoted by A∗(y, z). In other words, the dose level
A∗(y, z) ∈ {1, . . . , D} will be used to treat the next patient. For example, when pT =
0.2, for CRM with default prior hyperparameters, A∗CRM[(0, 0, 0, 0, 0, 1), (1, 1, 1, 2, 2,
2)] = 2; for mTPI-2 with 1 = 2 = 0.05, A∗mTPI-2[(0, 0, 0, 0, 0, 1), (1, 1, 1, 2, 2, 2)] = 1.
In the presence of pending outcomes, let A = A∗[(yobs,Ymis), z] denote the dose
assignment decision. Since Ymis is a vector of latent variables and A is a function of
Ymis, A is essentially a random variable. Under the Bayesian paradigm, the posterior
distribution of A is given by
Pr(A = a | H) =
∑
ymis:A∗[(yobs,ymis),z]=a
Pr(Ymis = ymis | H).(4.1)
Here,
Pr(Ymis = ymis | H) =
∫
ξ
∫
p
Pr(Ymis = ymis | H,p, ξ)pi(p, ξ | H)dpdξ
is the posterior predictive distribution of Ymis, and Pr(Ymis = ymis | H,p, ξ) is given
in (3.4). From a frequentist perspective, instead of marginalizing over the posterior
distribution of p and ξ, one could plug in the MLE of p and ξ. The probability (4.1)
is referred to as the POD, which accounts for the variability in the missing data and
directly reflects the confidence of every possible decision. The dose assignment for
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the next patient can be guided by the POD. For example, one may make the decision
with the highest POD, a∗ = arg maxa Pr(A = a | H).
4.2.1. Existing and New POD designs.
POD-TPI: We illustrate the POD designs through reviewing the POD-TPI design
(Zhou et al., 2020). POD-TPI assumes independent Beta(1, 1) priors on pz’s. With
a model for [T | Z, Y = 1] and an additional prior pi0(ξ), the posterior pi(p, ξ | H) ∝
pi0(p)pi0(ξ)L(p, ξ | H). By default, POD-TPI models [T | Z, Y = 1] with a piecewise
uniform distribution. The posterior predictive distribution of Ymis is then computed.
Finally, suppose the current dose is d, and let A = A∗[(yobs,Ymis), z] ∈ {d−1, d, d+1},
where A∗ is the decision function of mTPI-2. The PODs of possible decisions are
calculated, and the decision with the highest POD is executed, subject to additional
safety restrictions.
Apparently, the decision function A∗ can be based on any complete-data design.
The model for [T | Z, Y = 1] and priors on p and ξ can also be adjusted if desired.
In this way, we obtain a new class of POD designs, such as POD-CRM, POD-BOIN,
POD-keyboard, POD-SPM and POD-i3. We can categorize the POD designs ac-
cording to the corresponding complete-data designs A∗. For example, POD-TPI is
an interval-based nonparametric POD design.
5. Design Properties
In this section, we study large- and finite-sample properties of the aforementioned
time-to-event designs, with an emphasis on interval-based nonparametric designs.
5.1. Large-Sample Convergence Properties. Dose-finding studies are usually
carried out with relatively small sample sizes (10 to 50 subjects). Still, as noted in
Oron et al. (2011), large-sample convergence properties should be viewed as a neces-
sary quality criterion for dose-finding designs. In general, the large-sample properties
for a particular complete-data design should also hold for its time-to-event version,
as long as the DLT assessment window W and the patient accrual rate are both
finite. Intuitively, at time τ , all patients enrolled before (τ −W ) have finished their
DLT assessments, and only the patients enrolled within (τ −W, τ ] can have pending
outcomes. As τ →∞, the number of complete outcomes goes to infinity too, and the
number of pending outcomes is finite with probability one, making the contribution
of the pending outcomes negligible in the likelihood (3.2).
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In what follows, we present some general large-sample results for interval-based
nonparametric time-to-event designs. First, the following lemma establishes the con-
sistency of the posterior distribution and MLE of pz in a time-to-event setting when
(1) the number of patients treated by dose z, Nz, goes to infinity, and (2) the number
of pending outcomes at dose z, rz, is small compared to Nz.
Lemma 5.1 (consistency). Suppose the true distribution of the DLT outcome is
Pr(Yi = 1 | Zi = z) = p0z, and rz = o(Nz). (1) Let Cε = {pz : |pz − p0z| < ε}. Let
pi0(pz) be a prior distribution for pz such that pi0(pz ∈ Cε) > 0 for every ε > 0, and
the likelihood of pz is as in (3.2). Then, for every ε > 0, the posterior distribution
pi(pz ∈ Cε | H)→ 1 almost surely as Nz →∞. (2) The maximum likelihood estimator
pˆz → p0z almost surely as Nz →∞.
The proof is given in Appendix D.1. As a consequence of Lemma 5.1, we have the
following convergence theorem for interval-based nonparametric TITE designs.
Theorem 5.1 (convergence). Suppose the conditions in Lemma 5.1 are met. If there
is a dose d∗ satisfying p0d∗ ∈ (pT− 1, pT + 2), and d∗ is also the only dose such that
p0d∗ ∈ [pT − 1, pT + 2], then dose allocations in interval-based nonparametric TITE
designs converge almost surely to d∗.
Again, the proof is given in Appendix D.1. When the condition about d∗ is violated,
other convergence or oscillation results can be obtained as in Oron et al. (2011).
Next, the following lemma establishes the consistency of the dose-finding decisions
in interval-based nonparametric POD designs.
Lemma 5.2 (consistency). Suppose d is the current dose, which is neither the lowest
dose nor the highest dose. Suppose A∗ is the dose decision function of an interval-
based nonparametric complete-data design, and the conditions in Lemma 5.1 are met.
(1) If p0d ∈ (pT − 1, pT + 2), then ∃N0d > 0, when Nd > N0d, Pr(A = d | H) = 1
almost surely. (2) If p0d < pT − 1, then ∃N0d > 0, when Nd > N0d, Pr(A = d + 1 |
H) = 1 almost surely. (3) If p0d > pT + 2, then ∃N0d > 0, when Nd > N0d,
Pr(A = d− 1 | H) = 1 almost surely.
See Appendix D.1 for the proof. As a result, the convergence of dose allocations
(Theorem 5.1) also holds for interval-based nonparametric POD designs.
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For point-based designs or parametric designs, the consistency and convergence
results require additional assumptions. We direct the readers to Cheung and Chappell
(1999) for an example under the TITE-CRM setting.
5.2. Coherence Principles. The coherence principles are another quality criterion
for dose-finding designs motivated by ethical concerns in trial conduct. Cheung (2005)
introduced a coherence condition for time-to-event designs, which states that a time-
to-event design should not de-escalate from time τ to τ + τ ′ if no toxicity occurs
during [τ, τ + τ ′), and it should not escalate from time τ to τ + τ ′ if a toxicity occurs
within [τ, τ + τ ′) (for τ ′ → 0+). The formal definition is given below.
Definition 5.1 (Cheung, 2005). A time-to-event design A is coherent if (1) for any
τ, τ ′ > 0,
PrA
{A[H(τ + τ ′)] < A[H(τ)] | Y˜i(τ + τ ′)− Y˜i(τ) = 0 for all i} = 0;
and (2) for any τ > 0,
lim
τ ′→0+
PrA
{A[H(τ + τ ′)] > A[H(τ)] | Y˜i(τ + τ ′)− Y˜i(τ) = 1 for some i} = 0.
Cheung (2005) showed that the TITE-CRM design is coherent if the weight ρ(vi |
zi, ξ) is continuous and nondecreasing in vi, which is automatically satisfied under the
proposed framework (see Equation 3.1). In contrast, interval-based nonparametric
designs only use observations at the current dose to make dose-finding decisions thus
may be incoherent in the sense of Definition 5.1. For example, consider target DLT
rate pT = 0.2. Assume for two adjacent patients, the sequences of dose assignments
z = (2, 1) and DLT outcomes y = (1, 0). Using the BOIN or TITE-BOIN design with
default hyperparameters, the 3rd patient is assigned to dose level 2. Suppose by the
time the 4th patient is enrolled, the 3rd patient has finished DLT assessment with no
event. However, since the empirical DLT rate at dose 2 is 0.5, the 4th patient would
be assigned to dose 1. In other words, no toxicity occurs between the enrollment of
patients 3 and 4, but the dose level de-escalates from 2 to 1, which is incoherent. This
is because information at different dose levels is used to make the dose assignments
for patients 3 and 4. To avoid incoherent dose-finding decisions for interval-based
nonparametric designs, one may impose ad-hoc rules (such as those in Section 6).
On the other hand, one may still think such decisions are reasonable and consider
alternative coherence conditions for interval-based nonparametric designs, such as
the condition given below.
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Definition 5.2 (Interval coherence). An interval-based nonparametric time-to-event
design is interval coherent if (1) for any τ, τ ′ > 0, if the currently-administrated doses
just prior to τ and τ + τ ′ are the same (denoted by d), then
PrA
{A[H(τ + τ ′)] < A[H(τ)] | Y˜i(τ + τ ′)− Y˜i(τ) = 0 for all i s.t. Zi = d} = 0;
and (2) for any τ > 0, suppose the currently-administrated doses just prior to τ is d,
then
lim
τ ′→0+
PrA
{A[H(τ + τ ′)] > A[H(τ)] |
Y˜i(τ + τ
′)− Y˜i(τ) = 1 for some i s.t. Zi = d
}
= 0,
if the currently-administrated doses just prior to τ + τ ′ is also d.
In Appendix D.2, we show for a simple case that an interval-based nonparametric
TITE design is interval coherent in the sense of Definition 5.2.
Liu and Yuan (2015) defined another coherence condition for dose-finding designs,
which states that a dose-finding design is long-term memory coherent if it does not
de-escalate (or escalate) when the observed toxicity rate in the accumulative cohorts
at the current dose is lower (or higher) than the target toxicity rate. In other words,
suppose the current dose is d, then a design is long-term memory coherent if it
does not de-escalate (or escalate) when nd/(nd + md) < pT (or > pT). Under this
definition, time-to-event designs may be incoherent in escalation because the pending
outcomes may contribute additional evidence to counteract the toxic outcomes. If we
think such an escalation is reasonable, we may define that an escalation is incoherent
only if nd/(nd + md + rd) > pT. Alternatively, as in Lin and Yuan (2019), we may
also assign each pending outcome a weight ρ and calculate an adjusted toxicity rate
p˜d = nd/[nd +md +
∑N
i=1 ρi1(zi = d, bi = 0)]. For example, ρi = vi/W . De-escalation
is incoherent if p˜d < pT, and escalation is incoherent if p˜d > pT. However, the
specification of the weight can be arbitrary.
5.3. Overdosing Decisions and Incompatible Decisions. To better understand
the decision rules in TITE and POD designs, we introduce the concept of overdosing
decisions and incompatible decisions. A design’s frequency of making such decisions
measures the safety of this design.
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Overdosing decisions. We call a dose-finding decision A(H) an overdosing decision if
A(H) > d∗, where d∗ denotes the MTD. Similarly, we call A(H) < d∗ an underdosing
decision. For example, consider a trial with 2 doses, target DLT rate pT = 0.2, and
true DLT probabilities (p1, p2) = (0.2, 0.5). Then, d
∗ = 1 is the MTD, and any
decision that allocates a patient to dose 2 is an overdosing decision. Since the true
DLT probabilities are unknown in practice, we cannot check whether a decision is an
overdosing/underdosing decision in real-world trials.
The decision rules in TITE designs can be viewed as minimizing various loss func-
tions associated with overdosing/underdosing decisions. For example, in the TITE-
SPM design (Section 4.1.2), recall that γ represents the location of the MTD. Let
`(γ, γˆ) denote the loss of allocating the new patient to dose γˆ if γ is the true MTD,
and consider the 0-1 loss `(γ, γˆ) = 1(γ 6= γˆ). That is, there is a loss for an over-
dosing/underdosing decision. Then, the decision of allocating the new patient to
γˆ = arg maxγ pi(γ | H) minimizes the posterior expected loss.
Overdosing decisions apply to both complete-data and time-to-event designs and
are inevitable due to random sampling. As in Figure 5.1(a), suppose when the 4th
patient is enrolled, patients 1–3 have finished DLT assessment (assuming W = 28
days) with no event. Then, the 4th patient might be assigned to dose 2, which is
actually overly toxic. One may justify such a decision by sampling error.
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Figure 5.1. Examples for (a) an overdosing allocation and (b) an
incompatible decision (suppose patient 2 or 3 eventually experiences
DLT).
Incompatible decisions. We say that a time-to-event dose-finding decision A[H(τ)]
is incompatible with a complete-data decision A∗[H∗N(τ)] if A[H(τ)] 6= A∗[H∗N(τ)].
Here, H(τ) = {(Y˜i(τ), Vi(τ), Zi) : i ≤ N(τ)} represents the available time-to-event
information at time τ , and H∗N(τ) = {(Yi, Zi) : i ≤ N(τ)} represents the complete
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toxicity information for the first N(τ) patients that would have been observed if
these patients had completed their follow-up. For example, as in Figure 5.1(b),
consider a trial with 2 doses, target DLT rate pT = 0.2, true DLT probabilities
(p1, p2) = (0.1, 0.2) and DLT assessment window W = 28 days. Suppose when
the 4th patient arrives, patient 1 have finished DLT assessment with no event, and
patients 2 and 3 are still being followed without definitive outcomes. Using a time-
to-event design, the 4th patient might be treated by dose 2. However, it is possible
that patient 2 or 3 could eventually experience DLT, making the dose escalation for
patient 4 incompatible with a decision that uses complete data of patients 1–3. In
practice, we can check whether a time-to-event decision at time τ is incompatible
with a complete-data decision after all patients enrolled before τ have finished their
DLT assessment.
The decision rules in POD designs can be viewed as minimizing a loss function
associated with incompatible decisions. For example, in the POD-TPI design (Section
4.2.1), recall that A denotes the random mTPI-2 decision in the presence of pending
outcomes. Let `(A, Aˆ) denote the loss of making decision Aˆ if A is the true complete-
data decision, and consider the 0-1 loss `(A, Aˆ) = 1(A 6= Aˆ). Then, the decision
a∗ = arg maxa Pr(A = a | H) minimizes the posterior expected loss.
Incompatible decisions only apply to time-to-event designs and can be avoided by
following patients for the full length of the assessment window. We note that an
incompatible decision is not necessarily an overdosing/underdosing decision. In the
Figure 5.1(b) example, the incompatible decision actually allocates patient 4 to the
MTD. Still, since the true DLT probabilities are unknown in practice, such a decision
cannot be justified based on the observed data, and the safety review boards should
express concerns regarding the decision. Incompatible and overly aggressive decisions
(A[H(τ)] > A∗[H∗N(τ)]) are a major concern for drug companies and regulatory agen-
cies to use and approve time-to-event designs. Nevertheless, we next show that such
decisions may be eliminated in POD designs through a suspension rule.
6. Practical Considerations
6.1. Safety Rules. In addition to statistical modeling, safety rules play an impor-
tant role in dose-finding designs. For example, when a dose is deemed overly toxic,
future dose assignment to this dose or higher doses should be prohibited due to eth-
ical concerns. If the lowest dose is too toxic, the trial should be terminated and
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redesigned using lower doses. From a Bayesian perspective, toxicity can be quanti-
fied using posterior probability. Similar to Ji et al. (2010) and Yuan et al. (2016), we
consider the following safety rules.
Safety Rule 1 (Dose Exclusion): At any moment in the trial, if nz +mz ≥ 3 and
Pr(pz > pT | data) > ν for a pre-specified threshold ν close to 1, suspend dose z and
higher doses from the trial;
Safety Rule 2 (Early Termination): At any moment in the trial, if n1 +m1 ≥ 3
and Pr(p1 > pT | data) > ν for a pre-specified threshold ν close to 1, terminate the
trial due to excessive toxicity.
From a frequentist perspective, a dose z can be considered overly toxic if the lower
one-sided ν confidence interval of pz does not cover pT.
It is possible that a dose is considered overly toxic when some toxicity outcomes
at this dose are still pending. In this case, we allow this dose and upper doses to be
re-opened if some pending outcomes turn out to be safe and suggest this dose is no
longer overly toxic. If the lowest dose is considered overly toxic with some pending
outcomes, we temporarily suspend the trial. If later pending outcomes are observed
and suggest the lowest dose is no longer overly toxic, we resume the trial; otherwise,
the trial is permanently terminated. There is a positive probability that a dose is
excluded even if it is actually safe, or the trial is terminated early even when the
lowest dose is safe. This is the type I error associated with the safety rules.
Finally, similar to the implementation of the TITE-CRM (Normolle and Lawrence,
2006), we introduce one more safety rule to prevent risky dose escalation until at
least one patient at the current dose level has completed DLT assessment without
experiencing DLT.
Safety Rule 3 (Restricting Dose Escalation): Suppose the current dose is d. If
md < 1, dose escalation is not allowed.
In words, if there is no patient with confirmed safety outcome, escalation is not
allowed.
6.2. Enrollment and Suspension. Many existing designs (e.g., 3+3, mTPI, BOIN,
TITE-BOIN and POD-TPI) employ a cohort-based enrollment. The patients in
the same cohort are always treated by the same dose. Cohort-based enrollment is
especially necessary for complete-data designs, as the trial can take exceedingly long
to complete if each patient has to wait for the completion of the DLT assessment for
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the previous patient. Cohort-based enrollment can also help avoid overly fast dose
escalation and can be more convenient for trial administration. For most existing
designs, a common cohort size is 2 to 4. Cohort-based enrollment is not necessary
for time-to-event designs. The trial speed is no longer a concern, since new patients
can be enrolled when some previous outcomes are pending. The potentially fast dose
escalation might be a concern, but can be restricted with suspension rules, which we
discuss next.
For time-to-event designs, the dose assignment decision for a new patient may be
uncertain and risky if the toxicity outcomes of many previous patients are still pend-
ing. For example, three patients have been treated at the lowest dose and have been
followed up for a while, but none of them have completed the DLT assessment. In this
case, it might be too conservative to treat the fourth patient at the lowest dose as it
might be subtherapeutic, but it is also too risky to treat the fourth patient at a higher
dose as no safe outcome has been observed. Therefore, it may be more sensible to
temporarily suspend the trial until at least one outcome has been observed, although
trial suspension is not necessary from a purely statistical modeling perspective.
In the existing methods (e.g., Yuan et al., 2018 and Guo et al., 2019), the suspension
rule is usually defined based on the number of pending outcomes.
Ad-hoc Suspension Rule: Suppose the current dose is d. If rd > C for a pre-
specified threshold C, suspend the enrollment.
Here, C can be a fixed number (e.g. C = 3, Guo et al., 2019) or a portion of the
total number of patients at the current dose (e.g. C = Nd/2, Yuan et al., 2018).
Alternatively, as in Zhou et al. (2020), specifically for the POD designs, the POD
(4.1) can be directly used to calibrate the suspension and risk trade-off.
Probability Suspension Rule: Let a∗ = arg maxa Pr(A = a | H). If Pr(A < a∗ |
H) > qa∗ for a pre-specified threshold qa∗ , suspend the enrollment.
Here, a∗ is the optimal decision under the 0-1 loss, and Pr(A < a∗ | H) is the posterior
probability that a more conservative decision compared to a∗ should be made. In
other words, if the posterior probability that a more conservative decision than a∗
should be made is higher than some threshold qa∗ , the enrollment is suspended. The
threshold qa∗ can be different for different a
∗.
We note that the speed of the trial is solely determined by the suspension rule,
i.e., how many times an eligible patient is turned away. If no pending outcome is
allowed for making the dose assignment decision (C = 0), the time-to-event design
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reduces to a design using complete outcomes. On the other hand, if a trial never
suspends, all eligible patients are enrolled and treated immediately, and the trial
achieves its optimal speed. The Probability Suspension Rule allows a meaningful
calibration between trial speed and safety of the design. This will be clear later in
our numerical examples.
After patient enrollment is terminated and all DLT assessments are finished, the
trial completes, and the next step is to recommend an MTD. We summarize several
methods for MTD selection in Appendix E.
7. Simulation Studies
7.1. Simulation Set-up. We conduct simulation studies to compare the operating
characteristics of some TITE and POD designs that we have discussed in the previous
sections. We consider 18 dose-toxicity scenarios with target DLT probability pT = 0.2
or 0.3 and D = 7 dose levels. The 18 representative scenarios consist of the 16
scenarios reported in Yuan et al. (2018) and 2 additional scenarios that cover various
MTD locations. The scenarios are summarized in Appendix Table F.1.
We assume the DLT assessment window W = 28 days and use a maximum sample
size of N∗ = 36 patients. The time-to-toxicity for each patient, Ti, is generated from
a Weibull distribution with shape ζ1z and scale ζ2z, given the patient is treated by
dose z. That is,
(Ti | Zi = z) ∼Weibull(ζ1z, ζ2z).
The parameters ζ1z and ζ2z are chosen such that Pr(Ti ≤ W | Zi = z) = pz and
Pr(Ti ≤ W ∗ | Zi = z) = (1 − q)pz. Here W ∗ ∈ (0,W ) and q ∈ (0, 1) are arbitrary
numbers, meaning if a toxic outcome occurs within the assessment window, with
probability q it occurs within the interval (W ∗,W ]. The time between the accrual
of two consecutive patients is generated from an exponential distribution with rate
δ, which means the average wait time between two consecutive patients is 1/δ. We
consider the following three settings with different time-to-toxicity and accrual rate
profiles:
Setting 1 (default): inter-arrival time is 10 days, and 50% of DLTs occur in the
second half of the assessment window. This corresponds to δ = 0.1, W ∗ = W/2 and
q = 0.5;
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Setting 2 (more late-onset DLTs): inter-arrival time is 10 days, and 80% of DLTs
occur in the last quarter of the assessment window. This corresponds to δ = 0.1,
W ∗ = 3W/4 and q = 0.8;
Setting 3 (faster accrual): inter-arrival time is 5 days, and 50% of DLTs occur in
the second half of the assessment window. This corresponds to δ = 0.2, W ∗ = W/2
and q = 0.5.
We do not consider another setting with a longer DLT assessment window, as it would
be equivalent to faster accrual after rescaling the time.
7.2. Design Specifications. We consider the TITE-CRM, TITE-TPI, TITE-BOIN
(Section 4.1) and POD-TPI (Section 4.2) designs as examples of different types of
time-to-event designs. In addition, we include the mTPI-2 and R-TPI in the compari-
son as examples of complete-data designs and designs that allow for pending outcomes
but do not utilize time-to-event information, respectively. By default, TITE-BOIN,
POD-TPI and mTPI-2 enroll patients in cohorts of 3, and TITE-CRM and R-TPI
enroll patients one by one. For the newly proposed TITE-TPI, we employ a cohort-
based enrollment in sizes of 3. For a fair comparison, we impose the same Safety
Rules 1, 2 and 3 to all designs with ν = 0.95 (see Section 6.1). For TITE-CRM,
TITE-TPI and TITE-BOIN, we suspend the trial if the number of pending patients
at the current dose rd > Nd/2 (Ad-hoc Suspension Rule), as in Yuan et al. (2018).
For R-TPI, the trial is suspended if rd > 3 by default. For POD-TPI, we suspend
the trial according to the Probability Suspension Rule with qa∗ ≡ 0 for all a∗. That
is, the trial is suspended if there is a positive probability that the optimal decision
is overly aggressive. During trial suspension, the available patients are turned away.
More details about the design specifications are reported in Appendix F.2.
7.3. Performance Metrics. The performance of a design is evaluated based on the
following metrics.
(1) Selection & Allocation, including (1.1) percentage of correct selection (PCS) of
the MTD; (1.2) percentage of patients treated at the MTD (percentage of correct
allocation, PCA); (1.3) percentage of dose selection above the MTD (percentage
of overdosing selection, POS); (1.4) percentage of patients treated at doses above
the MTD (percentage of overdosing allocation, POA); and (1.5) percentage of
patients who have experienced toxicity (POT);
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(2) Risk, which is measured by the percentage of incompatible dose assignment de-
cisions (see Section 5.3). Recall that an incompatible decision refers to a decision
that is different from what would be made if complete outcomes were observed.
We are particularly concerned about the decisions that are overly aggressive, in-
cluding the decisions that (2.1) should be de-escalation based on complete data
but are stay (DS), (2.2) should be de-escalation but are escalation (DE), and
(2.3) should be stay but are escalation (SE);
(3) Speed, which is measured by the average trial duration (Dur).
Metrics (1.1)–(1.5) assess the design’s performance in selecting the right dose as the
MTD and assigning patients to appropriate doses. Metrics (2.1)–(2.3) are about the
risk associated with allowing patient enrollment in the presence of pending outcomes.
In particular, the incompatible decisions of the time-to-event designs are obtained
by comparing with their complete-data counterparts. For example, TITE-CRM is
compared with CRM, and POD-TPI is compared with mTPI-2. Metric (3) is about
the speed of the trial.
7.4. Simulation Results. For each dose-toxicity scenario in Appendix Table F.1, we
simulate 4,000 trials with each design. Table 7.1 summarizes the results by averaging
over the 18 scenarios. The scenario-specific results under Setting 1 are reported in
Appendix F.3. The performances of the designs are generally similar if averaged over
scenarios, although they may have a large variation across different scenarios. The
comparison among mTPI-2, R-TPI, TITE-TPI and POD-TPI illustrates the different
behaviors of various extensions of the same complete-data design.
On average, the trial duration is shortened by about 150–170 days using TITE
designs, and is shortened by about 50–60 days using POD designs. This is a major
benefit for drug development. The trial durations under TITE-TPI, TITE-CRM and
TITE-BOIN are highly similar, because the same suspension rule is imposed. The
trial durations under POD-TPI are longer, because a more conservative suspension
rule is used, resulting in more patients being turned away. The PCS of the time-
to-event designs is comparable to the complete-data design (mTPI-2). This is not
surprising, because we always use complete outcomes to make the final selection
of MTD. In the presence of pending outcomes, time-to-event designs may lead to
incompatible assignments. For example, in Table 7.1, the DS, DE and SE of the
TITE designs are non-zero, meaning the TITE designs sometimes make incompatible
and aggressive decisions. Nevertheless, through the Probability Suspension Rule,
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Table 7.1. Summary of simulation results under 18 dose-toxicity sce-
narios and 3 time-to-toxicity and accrual rate settings. Values shown
are averages over simulated trials and scenarios. Six designs, mTPI-2,
R-TPI, TITE-TPI, POD-TPI, TITE-CRM and TITE-BOIN, are com-
pared. PCS, PCA, POS, POA, POT are in %, DS, DE and SE are in
1/103, and Dur is in days.
Method
Selection & Allocation Risk Speed
PCS PCA POS POA POT DS DE SE Dur
Setting 1
mTPI-2 51.9 34.4 15.7 22.5 19.4 0.0 0.0 0.0 594
R-TPI 48.1 32.9 13.5 20.1 18.3 33.5 0.0 0.0 521
TITE-TPI 51.6 32.5 16.2 21.4 18.8 13.1 3.3 21.7 435
POD-TPI 51.0 32.9 16.0 21.1 18.7 0.0 0.0 0.0 541
TITE-CRM 55.4 36.3 29.8 27.0 21.3 48.5 0.2 7.9 438
TITE-BOIN 54.1 32.5 21.8 21.1 18.7 10.4 3.0 18.4 435
Setting 2
mTPI-2 52.1 34.2 16.0 22.8 19.5 0.0 0.0 0.0 613
R-TPI 50.0 33.5 14.7 22.0 19.1 51.8 0.0 0.0 543
TITE-TPI 51.3 31.8 17.6 23.5 19.5 21.8 7.5 33.0 444
POD-TPI 51.0 32.6 16.1 21.9 19.0 0.0 0.0 0.0 558
TITE-CRM 55.3 35.4 29.4 29.4 22.1 80.7 0.9 14.8 449
TITE-BOIN 53.8 32.3 23.7 23.7 19.7 22.6 7.2 31.9 444
Setting 3
mTPI-2 52.0 34.2 16.1 23.2 19.6 0.0 0.0 0.0 438
R-TPI 48.5 32.6 14.2 20.4 18.4 45.7 0.0 0.0 387
TITE-TPI 51.0 31.5 15.8 21.1 18.6 15.8 3.7 25.5 290
POD-TPI 50.7 31.9 15.9 20.5 18.4 0.0 0.0 0.0 379
TITE-CRM 55.1 35.0 29.8 26.8 21.1 58.1 0.3 9.8 304
TITE-BOIN 53.8 31.8 21.5 20.5 18.4 12.9 3.0 21.4 290
POD designs may completely eliminate the chance of making these decisions. For
example, in Table 7.1, DS, DE and SE are not observed for POD-TPI. This is a major
advantage for POD designs. Although the time-to-event designs make incompatible
and aggressive decisions, their PCA and POA are not necessarily higher, as they
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also make incompatible and conservative decisions (not shown). With more late-
onset toxicities (Setting 2) or faster patient accrual (Setting 3), the performances
of the time-to-event designs are slightly decreased. In particular, the frequencies
of incompatible decisions for TITE designs under Settings 2 and 3 are generally
increased compared to the results under Setting 1. Lastly, there is always a trade-off
among the different performance metrics. For example, TITE-CRM has the highest
PCS and high PCA, but it also has the highest POS and high POA and POT due
to the more aggressive decision rules and MTD selection. R-TPI has the lowest POS
and low POA and POT, but as a compromise, its PCS is slightly lower due to the
more conservative decisions.
Sensitivity of time-to-toxicity model. We have listed several possible specifications of
the time-to-toxicity model in Section 3.2 and Appendix B. To explore how these spec-
ifications can affect the operating characteristics of a design, we conduct additional
simulation studies using POD-TPI as an example. We consider five different time-
to-toxicity models: (1) uniform distribution; (2) piecewise uniform distribution with
3 sub-intervals (default); (3) piecewise uniform distribution with 9 sub-intervals; (4)
discrete hazard model; and (5) piecewise constant hazard model with 3 sub-intervals.
More details about the model specifications are reported in Appendix F.4. Recall
that the true distribution of [T | Z, Y = 1] is a truncated Weibull distribution.
Table 7.2 summarizes the simulation results. The performances of POD-TPI under
different time-to-toxicity models are generally similar. Importantly, no matter what
time-to-toxicity model is used, the Probability Suspension Rule guarantees that no
incompatible and aggressive decisions are ever made. The average number of DLTs in
the trial is N∗×POT ≈ 36×20% = 7.2. As a result, there is very limited information
for estimating the true time-to-toxicity distribution, and the specification of the time-
to-toxicity model matters little. Under the discrete hazard model or the piecewise
constant hazard model, the pending patients are weighted less if many DLTs are
late-onset, making the design safer in such situations (in terms of lower POA and
POT). This is consistent with the results reported in Yuan and Yin (2011) and Liu
et al. (2013).
Sensitivity of ad-hoc rules. As described in Section 6, the dose-finding decisions are
always subject to additional ad-hoc rules. To explore how these rules can affect
the operating characteristics of a design, we conduct additional simulation studies
under Setting 1 using POD-TPI. We consider the following five sets of rules: (1)
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Table 7.2. Summary of simulation results using POD-TPI under 5
different time-to-toxicity models. Values shown are averages over sim-
ulated trials and scenarios. PCS, PCA, POS, POA, POT are in %, DS,
DE and SE are in 1/103, and Dur is in days.
Time-to-toxicity Model
Selection & Allocation Risk Speed
PCS PCA POS POA POT DS DE SE Dur
Setting 1
Uniform 50.7 32.8 16.1 21.3 18.8 0.0 0.0 0.0 541
Piecewise Uniform 3 51.0 32.9 16.0 21.1 18.7 0.0 0.0 0.0 541
Piecewise Uniform 9 51.3 33.0 15.8 21.1 18.7 0.0 0.0 0.0 541
Discrete hazard 48.6 28.1 15.9 18.7 17.0 0.0 0.0 0.0 529
Piecewise hazard 3 50.2 31.2 15.8 20.0 18.1 0.0 0.0 0.0 534
Setting 2
Uniform 51.0 32.5 16.0 21.6 18.9 0.0 0.0 0.0 556
Piecewise Uniform 3 51.0 32.6 16.1 21.9 19.0 0.0 0.0 0.0 558
Piecewise Uniform 9 50.6 32.7 16.0 21.9 19.1 0.0 0.0 0.0 560
Discrete hazard 48.3 27.3 15.6 18.7 16.9 0.0 0.0 0.0 536
Piecewise hazard 3 50.5 30.6 15.9 20.3 18.1 0.0 0.0 0.0 545
Setting 3
Uniform 50.1 31.8 15.8 20.4 18.4 0.0 0.0 0.0 379
Piecewise Uniform 3 50.7 31.9 15.9 20.5 18.4 0.0 0.0 0.0 379
Piecewise Uniform 9 50.5 31.7 15.7 20.4 18.4 0.0 0.0 0.0 379
Discrete hazard 47.3 26.2 15.7 17.9 16.4 0.0 0.0 0.0 374
Piecewise hazard 3 50.2 30.8 15.7 19.7 18.0 0.0 0.0 0.0 377
Probability Suspension Rule + cohort-based enrollment in sizes of 3 (default); (2)
Ad-hoc Suspension Rule + cohort-based enrollment in sizes of 3; (3) No Suspension +
cohort-based enrollment in sizes of 3; (4) Probability Suspension Rule + rolling (one
by one) enrollment; and (5) Ad-hoc Suspension Rule + rolling enrollment. Safety
Rules 1, 2 and 3 are imposed under all settings. In particular, we set ν = 0.95 in
Safety Rules 1 and 2, C = Nd/2 in the Ad-hoc Suspension Rule and qa∗ ≡ 0 in the
Probability Suspension Rule.
The performance of POD-TPI under each rule set is reported in Table 7.3. Under
rule set 1, the strict thresholds qa∗ = 0 in the Probability Suspension Rule guarantee
30 T. ZHOU AND Y. JI
that no incompatible and aggressive decision can be made. These are the most con-
servative choices in practice. Alternatively, one may use less conservative thresholds,
e.g., qa∗ = 0.1, such that certain risks are allowed to achieve faster trials. This may
still be acceptable if a benchmark is set as risk tolerance. See Zhou et al. (2020) for
more details and numerical results. Under rule set 2, POD-TPI has a faster speed
(compared to that under rule set 1) at the cost of making some incompatible and ag-
gressive decisions. Specifically, the trial duration under rule set 2 is similar to that of
TITE-TPI, TITE-CRM and TITE-BOIN in Table 7.1, because the same suspension
rule is used. Under rule set 3, POD-TPI abandons the suspension rule and achieves
its fastest speed at the cost of lower PCS and PCA. Under rule set 4, the trial needs
to be frequently suspended after each patient is treated due to the strict thresholds
in the Probability Suspension Rule, and as a result, the trial duration is prolonged.
Finally, the results under rule set 5 are similar to those under rule set 2.
Table 7.3. Summary of simulation results using POD-TPI under 5
different sets of rules. Values shown are averages over simulated trials
and scenarios. PCS, PCA, POS, POA, POT are in %, DS, DE and SE
are in 1/103, and Dur is in days.
Suspension Cohort
Selection & Allocation Risk Speed
PCS PCA POS POA POT DS DE SE Dur
Setting 1
Prob 3 51.0 32.9 16.0 21.1 18.7 0.0 0.0 0.0 541
Ad-hoc 3 51.7 32.6 17.9 24.1 19.8 21.4 3.8 23.0 437
No 3 50.1 28.0 17.5 20.5 17.6 14.5 5.9 26.7 364
Prob 1 50.9 34.6 15.2 22.9 19.6 0.0 0.0 0.0 702
Ad-hoc 1 50.8 33.6 17.7 25.6 20.5 23.2 6.2 14.8 431
8. Concluding Remarks
We have presented a general statistical framework for time-to-event modeling in
dose-finding trials. Two classes of time-to-event designs, TITE designs and POD
designs, can be built upon the framework. We have demonstrated that existing time-
to-event designs (such as TITE-CRM, TITE-BOIN and TITE-keyboard) fall within
this framework, and new time-to-event designs (such as TITE-SPM, TITE-TPI and
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POD-CRM) can be developed under this framework. The framework opens the way
to a deeper study of time-to-event designs.
We have discussed and studied theoretical properties of time-to-event designs with
an emphasis on interval-based nonparametric designs. A future direction is to inves-
tigate more on these theoretical properties, especially for point-based or parametric
designs.
We have evaluated the operating characteristics of several designs through com-
puter simulations. As we have seen, there is no single design that outperforms the
other designs in all aspects. To choose one specific design to use in practice, we may
run large-scale simulations and consider a loss function of the form
` = −`1PCS− `2PCA + `3POS + `4POA + `5POT+
`6DS + `7DE + `8SE + `9Dur,
where `1, . . . , `9 ≥ 0. The design that minimizes the loss function can be selected
as the winner. Usually, safety is the major concern. For example, the safety review
boards may express concerns regarding incompatible and aggressive decisions. If the
probability of such decisions needs to be controlled, we recommend the POD designs
together with the Probability Suspension Rule.
Lastly, the proposed framework can be extended to accommodate non-binary end-
points. For example, ordinal endpoints that account for multiple toxicity grades
(Meter et al., 2012; Mu et al., 2019). Another direction for further exploration is to
apply the framework to drug combination trials (Wages et al., 2011; Liu and Ning,
2013) or phase I/II trials that simultaneously consider toxicity and efficacy (Jin et al.,
2014).
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Appendix A. Review of Complete-Data Designs
In this section, we provide a brief review of six main-stream complete-data dose-
finding designs: CRM, BOIN, mTPI-2, keyboard, SPM and i3+3. The 3+3 design is
excluded from the discussion, as it does not allow the specification of a particular DLT
target pT and a maximum sample size. It is widely recognized that 3+3 has worse
performance than, e.g., mTPI (Ji and Wang, 2013). We denote by Nz =
∑N
i=1 1(Zi =
z), nz =
∑N
i=1 1(Zi = z, Yi = 1) and mz =
∑N
i=1 1(Zi = z, Yi = 0) the total number
of patients, number of DLTs and number of non-DLTs at dose z, respectively.
A.1. Continual Reassessment Method (CRM). The CRM design assumes a
dose-toxicity response curve pz = φ(z, α), such that φ monotonically increases with
z, and α is an unknown parameter. For example, a commonly used dose-toxicity curve
is φ(z, α) = p
exp(α)
0z , where p0z’s are pre-specified constants satisfying p01 < · · · < p0D.
The likelihood becomes
L(α | y, z) =
N∏
i=1
φ(zi, α)
yi [1− φ(zi, α)]1−yi .
Inference on α can be Bayesian (O’Quigley et al., 1990) or be based on maximum
likelihood (O’Quigley and Shen, 1996). From a Bayesian perspective, a prior distribu-
tion pi0(α) is specified for α (for example, α ∼ N(0, 1.342)), leading to the posterior
pi(α | y, z) ∝ pi0(α)L(α | y, z). The DLT probabilities can thus be estimated by
pˆz =
∫
φ(z, α)pi(α | y, z)dα. On the other hand, the maximum likelihood estimate
(MLE) for α is αˆ = arg maxα L(α | y, z), and pz can be estimated by pˆz = φ(z, αˆ).
In both cases, the dose d∗ = arg minz |pˆz − pT| is recommended for the next patient,
subject to some practical safety restrictions (Goodman et al., 1995; Cheung, 2005).
A.2. Bayesian Optimal Interval (BOIN) Design. We refer to the local BOIN
design (Liu and Yuan, 2015), which considers a hypothesis test of three hypotheses:
H0 : pd = pT, H1 : pd = pL, H2 : pd = pR.(A.1)
Here d is the current dose level, pL denotes the highest toxicity probability that is
deemed subtherapeutic such that dose escalation should be made, and pR denotes the
lowest toxicity probability that is deemed overly toxic such that dose de-escalation
is required. The quantities pL and pR need to be pre-specified by physicians. As-
suming equal prior weights on the three hypotheses, the optimal decision boundaries
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λL(pT, pL) and λR(pT, pR) minimizing the decision error rate are,
λL = log
(
1− pL
1− pT
)/
log
[
pT(1− pL)
pL(1− pT)
]
,
λR = log
(
1− pT
1− pR
)/
log
[
pR(1− pT)
pT(1− pR)
]
.
Let pˆd = nd/Nd denote the MLE for pd. If pˆd ≤ λL, the dose is escalated for the
next patient; if pˆd ≥ λR, the dose is de-escalated; and otherwise, the same dose
level is retained. Note that λL and λR can be pre-specified without the optimization
procedure in Liu and Yuan (2015). When they are pre-specified, BOIN uses essentially
the same up-and-down rules as the cumulative cohort design (Ivanova et al., 2007).
A.3. mTPI-2 Design. The mTPI-2 design considers a partition of the [0, 1] interval
into an equivalence interval IE = [pT − 1, pT + 2], an underdosing interval IU =
[0, pT − 1) and an overdosing interval IO = (pT + 2, 1]. Any dose with toxicity
probabilities inside IE is considered a true MTD, and the doses in IU (or IO) are
considered subtherapeutic (or overly toxic) and are deemed lower (or higher) than
the MTD. The values 1 and 2 need to be specified by physicians. The intervals IU
and IO are further divided into several sub-intervals, IU0 , . . . , IUK1 and IO0 , . . . , IOK2 ,
such that all the sub-intervals have the same length (1 + 2) except for the two
intervals (IU0 and IO0) reaching the boundary of [0, 1]. Let d denote the current dose
level, and let model Md = j represent {pd ∈ Ij}, j = U0, . . . ,UK1 ,E,O0, . . . ,OK2 .
The mTPI-2 design is based on the following hierarchical model,
Pr(Md = j) = 1/(K1 +K2 + 3), for j = U0, . . . ,UK1 ,E,O0, . . . ,OK2 ;
pd | Md ∼ TBeta(1, 1; IMd),
where TBeta(·, ·; I) represents a truncated beta distribution restricted to interval I.
The dose assignment decision for the next patient is to escalate, stay or de-escalate,
if arg maxj Pr(Md = j | nd,md) belongs to {U0, . . . ,UK1}, equals E or belongs to
{O0, . . . ,OK2}, respectively.
A.4. Keyboard Design. The keyboard design, similar to the mTPI-2 design, con-
siders a partition of the [0, 1] interval into equal-length sub-intervals (except for the
two boundary intervals IU0 and IO0). The equal-length sub-intervals IU1 , . . . , IUK1 ,
IE, IO1 , . . . , IOK2 are referred to as keys, and the equivalence interval IE is referred to
as the target key. The two boundary intervals IU0 and IO0 may not be long enough to
form a key. Instead of using a hierarchical prior for pd, keyboard considers a simple
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prior pd ∼ Beta(1, 1), leading to the posterior pd | nd,md ∼ Beta(nd + 1,md + 1).
The dose assignment decision for the next patient is to escalate, stay or de-escalate,
if arg maxj Pr(pd ∈ Ij | nd,md) belongs to {U1, . . . ,UK1}, equals E or belongs to
{O1, . . . ,OK2}, respectively.
A.5. Semiparametric Dose Finding Method (SPM). The SPM directly models
the the location of the MTD γ, 1 ≤ γ ≤ D. Conditional on γ being the MTD, the
support of pz is restricted to
supp(pz) =

[0, pT − 1), if z < γ;
[pT − 1, pT + 2], if z = γ;
(pT + 2, 1], if z > γ.
This restriction guarantees the partial ordering of the pz’s. The partition of the [0, 1]
interval in the SPM coincides with the mTPI and mTPI-2 designs, while the center
interval is interpreted differently as an indifference interval (Cheung and Chappell,
2002). The priors on γ and pz’s can be specified as follows,
Pr(γ = z∗) = κz∗ ,
pz | γ ∼ TBeta(cθγz + 1, c(1− θγz ) + 1; Iγz ).
Here κz∗ , c and θ
γ
z are hyperparameters, and I
γ
z = IU, IE or IO for z < γ, z = γ or
z > γ, respectively. The posterior pi(γ,p | y, z) ∝ pi0(γ)pi0(p | γ)L(p | y, z), and the
dose γˆ = arg maxγ pi(γ | y, z) is recommended for the next patient, again subject to
some restrictions as in the CRM design.
A.6. i3+3 Design. The i3+3 design consists of a set of algorithmic decision rules,
that is, model free. Similar to mTPI-2, it considers a partition of the [0, 1] interval
into IE, IU and IO. Suppose the current dose is d. If nd/Nd ∈ IU, the decision is
escalation. If nd/Nd ∈ IE, the decision is stay. If nd/Nd ∈ IO, the decision is stay
when (nd − 1)/Nd ∈ IU and is de-escalation otherwise.
Appendix B. Modeling Time-to-Toxicity Data
We introduce several examples for the specification of fT |Z,Y (t | z, Y = 1, ξ). That
is, the model for the conditional distribution [T | Z, Y = 1]. Recall that the event
Y = 1 is equivalent to T ≤ W .
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B.1. Uniform Distribution. The simplest choice for the conditional distribution
of T is a uniform distribution,
T | Z, Y = 1 ∼ Unif(0,W ).
This leads to the conditional pdf,
fT |Z,Y (t | z, Y = 1) = 1/W,
where no additional parameter ξ is involved. The weight function in this case is
ρ(t | z) = t/W . The uniform distribution, albeit simple, has been shown to be
sufficient in many cases (Cheung and Chappell, 2000). It is the default choice in
Cheung and Chappell (2000), Yuan et al. (2018) and Lin and Yuan (2019).
B.2. Piecewise Uniform Distribution. A more flexible specification for the con-
ditional distribution of T is a piecewise uniform distribution. The interval (0,W ] is
first partitioned into K sub-intervals {(hk−1, hk], k = 1, . . . , K}, where 0 = h0 < h1 <
· · · < hK = W . Next, each sub-interval is assigned a weight ωk,
∑K
k=1 ωk = 1. Con-
ditional on Y = 1, T falls into (hk−1, hk] with probability ωk and follows a uniform
distribution within this interval. The conditional pdf of T is thus
fT |Z,Y (t | z, Y = 1, ξ) = ωk · 1
hk − hk−1 , for hk−1 < t ≤ hk.(B.1)
The weight function is
ρ(t | z, ξ) =
K∑
k=1
ωkβ(t, k),
where
β(t, k) =

1, if t > hk;
t−hk−1
hk−hk−1 , if t ∈ (hk−1, hk], k = 1, . . . , K;
0, otherwise.
(B.2)
The parameters ξ = (K,h1, . . . , hK−1, ω1, . . . , ωK). The number of sub-intervals K
and the interval boundaries hk’s are usually fixed. For example, K = 3 and hk =
kW/K for k = 1, . . . , K, representing three sub-intervals with equal lengths. Alterna-
tively, let n denote the number of observed DLTs, and let 0 < t(1) ≤ · · · ≤ t(n) ≤ W
denote the ordered observed DLT times. One can set K = n + 1, hk = t(k) for
k = 1, . . . , n and hK = W . The weights of the sub-intervals ωk’s can be fixed if
prior information is available or can be estimated otherwise. A Dirichlet distribution
can be used as the prior for (ω1, . . . , ωK). The piecewise uniform distribution with
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equal-length sub-intervals and fixed sub-interval weights is considered in Yuan et al.
(2018) and Lin and Yuan (2019). The piecewise uniform distribution with empirically
calibrated sub-intervals and same sub-interval weights ωk = 1/K is equivalent to the
adaptive weighting scheme in Cheung and Chappell (2000).
B.3. Discrete Hazard Model. The conditional distribution of T can be constructed
from a discrete hazard model. Let 0 < t(1) ≤ · · · ≤ t(n) ≤ W denote the ordered
observed DLT times, let h1 < · · · < hK−1 represent the distinct DLT times that are
strictly less than W , and let hK = W . We assume T can only take discrete values at
the hk’s given Y = 1. Let ωk = Pr(T = hk | T ≥ hk, Y = 1) represent the discrete
hazard at time hk, with ωK = 1. The conditional probability mass function of T is
Pr(T = hk | Z, Y = 1, ξ) = ωk
k−1∏
j=1
(1− ωj), k = 1, . . . , K,
and the weight function is
ρ(t | z, ξ) = Pr(T ≤ t | Z, Y = 1, ξ) = 1−
∏
k:hk≤t
(1− ωk).
The discrete hazard model is used in Yuan and Yin (2011).
B.4. Piecewise Constant Hazard Model. The conditional distribution of T can
also be constructed from a piecewise constant hazard model. Again, consider a par-
tition of (0,W ] into K sub-intervals {(hk−1, hk], k = 1, . . . , K}, where 0 = h0 < h1 <
· · · < hK = W . Given Y = 1, we assume the hazard of toxicity is ωk in the interval
(hk−1, hk]. This leads to the conditional pdf,
fT |Z,Y (t | z, Y = 1, ξ) = ω1(t∈(hk−1,hk])k exp
[
−
K∑
k=1
ωk(hk − hk−1)β(t, k)
]
,(B.3)
where β(t, k) is the same as in Equation (B.2). The weight function is
ρ(t | z, ξ) = 1− exp
[
−
K∑
k=1
ωkβ(t, k)
]
.
This model specification is used in Liu et al. (2013) and Jin et al. (2014). We note
that although this specification can facilitate inference, it has a potential pitfall:∫W
0
fT |Z,Y (t | z, Y = 1, ξ)dt = ρ(W | z, ξ) < 1, which means (B.3) is not a proper pdf
in (0,W ].
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B.5. Rescaled Beta Distribution. Another possible specification for the condi-
tional distribution of T is a rescaled beta distribution. Specifically,
T/W | Z, Y = 1, ξ1, ξ2 ∼ Beta(ξ1, ξ2),
and
fT |Z,Y (t | z, Y = 1, ξ) = 1
B(ξ1, ξ2)
· t
ξ1−1(W − t)ξ2−1
W ξ1+ξ2−1
,
where B(·, ·) is the beta function. The rescaled beta distribution is considered in Lin
and Yuan (2019). Gamma distribution priors can be put on ξ1 and ξ2.
In all the examples above, the conditional distribution fT |Z,Y (t | z, Y = 1, ξ) does
not depend on the dose, which implies T and Z are conditionally independent given
Y = 1. This allows pooling of time-to-event information across doses. If desired,
it is easy to let fT |Z,Y (t | z, Y = 1, ξ) vary across doses. For example, in Equation
(B.1) the parameters ωk’s can be changed to dose-specific parameters ωzk’s. Since the
time-to-event data are usually sparse in dose-finding trials, information borrowing is
recommended for estimating dose-specific parameters using, e.g., hierarchical priors.
Appendix C. Inference on the Toxicity Probabilities
C.1. Inference Based on the Survival Likelihood. With the survival likelihood
(3.2), one can proceed with inference on p. In this section, we propose some general
strategies to conduct such inference.
Independent Metropolis-Hastings Algorithm. From a Bayesian perspective, prior dis-
tributions pi0(p) and pi0(ξ) are specified for p and ξ. Inference on p is summarized
in the posterior distribution,
pi(p, ξ | H) ∝ pi0(p)pi0(ξ)L(p, ξ | H).
In general, the posterior is not available in closed form, and Monte Carlo simulation
is needed to approximate the posterior. When conjugate priors are used, the in-
dependent Metropolis-Hastings (IMH) algorithm (Robert and Casella 2004, Section
7.4) can be employed. Let L˜(p, ξ | H) denote the complete case likelihood (i.e. the
likelihood for the patients with complete outcomes),
L˜(p, ξ | H) =
N∏
i=1
[
p1(y˜i=1)zi (1− pzi)1(y˜i=0,vi=W )fT |Z,Y (vi | zi, Y = 1, ξ)1(y˜i=1)
]
.
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The complete case likelihood can be factorized as L˜ = L˜1(p | H)L˜2(ξ | H), where
L˜1(p | H) =
N∏
i=1
[
p1(y˜i=1)zi (1− pzi)1(y˜i=0,vi=W )
]
, and
L˜2(ξ | H) =
N∏
i=1
[
fT |Z,Y (vi | zi, Y = 1, ξ)1(y˜i=1)
]
.
To implement the IMH algorithm, we first randomly initialize p(0) and ξ(0). At
iteration j (j = 1, 2, . . .), we propose p˜ and ξ˜ from the complete case posteriors,
p˜i(p | H) ∝ pi0(p)L˜1(p | H), and p˜i(ξ | H) ∝ pi0(ξ)L˜2(ξ | H).
If conjugate priors are specified for p and ξ (e.g., a beta distribution prior for pz),
the complete case posteriors are available in closed form. The proposals are accepted
with probability
qacc
(
p˜, ξ˜;p(j−1), ξ(j−1)
)
= 1 ∧
∏
i:y˜i=0,vi<W
1− ρ(vi | zi, ξ˜)p˜zi
1− ρ(vi | zi, ξ(j−1))p(j−1)zi
,
and otherwise, p(j−1) and ξ(j−1) are retained. Under standard regularity conditions
(Robert and Casella, 2004), the sequence {p(j), j = 1, 2, . . .} has a stationary distri-
bution pi(p | H).
Partial Derivatives of the Log-Likelihood. From a frequentist perspective, the MLE pˆ
can be used as an estimate for p. We can calculate (pˆ, ξˆ) = arg maxp,ξ L(p, ξ | H)
by taking partial derivatives of the log-likelihood with respect to all the parameters.
It suffices to solve the following equations,
∂ logL
∂pz
=
nz
pz
− mz
1− pz −
∑
i:y˜i=0,vi<W,zi=z
ρ(vi | zi, ξ)
1− ρ(vi | zi, ξ)pz = 0,
and
∂ logL
∂ξk
= −
∑
i:y˜i=0,vi<W
pzi
1− ρ(vi | zi, ξ)pz
∂ρ(vi | zi, ξ)
∂ξk
+
∑
i:y˜i=1
1
fT |Z,Y (vi | zi, Y = 1, ξ)
∂fT |Z,Y (vi | zi, Y = 1, ξ)
∂ξk
= 0.
C.2. Equivalence of the Survival Likelihood and the Augmented Likeli-
hood.
Proof of Proposition 3.1. For notational clarity, let Lmis(p, ξ | H) denote the derived
data likelihood by marginalizing (3.3) over ymis, and let Lsur(p, ξ | H) denote the
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survival likelihood (3.2). We have
Lmis(p, ξ | H) =
∑
ymis∈{0,1}r
Lmis(p, ξ,ymis | H)
=
∏
i:bi=1
[
p1(yi=1)zi (1− pzi)1(yi=0)fT |Z,Y (vi | zi, Yi = 1, ξ)1(yi=1)
]
×
∏
i:bi=0
{
pzi [1− ρ(vi | zi, ξ)] + (1− pzi)
}
=
N∏
i=1
{
p1(yi=1,bi=1)zi (1− pzi)1(yi=0,bi=1)×
fT |Z,Y (vi | zi, Yi = 1, ξ)1(yi=1,bi=1) [1− ρ(vi | zi, ξ)pzi ]1(bi=0)
}
= Lsur(p, ξ | H).
Here, r =
∑N
i=1 1(bi = 0) =
∑D
z=1 rz is the number of missing outcomes. The last
equation holds because {Y˜i = 1} is equivalent to {Yi = 1, Bi = 1}, and {Y˜i = 0}
contains {Yi = 0, Bi = 1} and {Bi = 0}. 
C.3. Inference Based on the Augmented Likelihood. With the augmented
likelihood (3.3), one can proceed with inference on p. Specifically, (3.3) can be
factorized into L(p, ξ,ymis | H) = L1(p,ymis | H)L2(ξ,ymis | H), where
L1(p,ymis | H) =
N∏
i=1
[
p1(yi=1)zi (1− pzi)1(yi=0)
]
, and
L2(ξ,ymis | H) =
N∏
i=1
{
fT |Z,Y (vi | zi, Y = 1, ξ)1(yi=1,bi=1) [1− ρ(vi | zi, ξ)]1(yi=1,bi=0)
}
.
This factorization facilitates inference.
Data Augmentation. From a Bayesian perspective, the posterior distribution pi(p | H)
can be simulated using the data augmentation (DA) method (Tanner and Wong,
1987; Higdon, 1998). We first randomly initialize p(0), ξ(0) and y
(0)
mis. At iteration j
(j = 1, 2, . . .), implement the following procedures until the stationary distribution is
reached and the desired number of posterior samples is obtained.
(1) Imputation step. Sample y
(j)
mis | H,p(j−1), ξ(j−1) from (3.4);
(2) Posterior step. Sample p(j) | H,y(j)mis and ξ(j) | H,y(j)mis from the corresponding
posteriors,
pi(p | H,y(j)mis) ∝ pi0(p)L1(p,y(j)mis | H), and
pi(ξ | H,y(j)mis) ∝ pi0(ξ)L2(ξ,y(j)mis | H).
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If conjugate priors are specified for p and ξ (e.g., a beta distribution prior for
pz), the above posteriors are available in closed form. Through this procedure,
we obtain a Markov chain {p(j), ξ(j),y(j)mis, j = 1, 2, . . .}, whose stationary distri-
bution is pi(p, ξ,ymis | H) under standard regularity conditions. The sequence
{p(j), j = 1, 2, . . .} has a marginal stationary distribution pi(p | H).
Expectation Maximization. From a frequentist perspective, the MLE of p can be
calculated through the expectation maximization (EM) algorithm (Dempster et al.,
1977). We first randomly initialize p(0), ξ(0) and y
(0)
mis. At iteration j (j = 1, 2, . . .),
implement the following procedures until the desired convergence criteria is met.
(1) Expectation step. Set y
(j)
mis at the expected values as in (3.4) given the current
parameter estimates p(j−1) and ξ(j−1);
(2) Maximization step. Set p(j) and ξ(j) at the corresponding MLEs of (3.3), using
(yobs,y
(j)
mis) as the full data. That is,
p(j) = arg max
p
L1(p,y
(j)
mis | H), and
ξ(j) = arg max
ξ
L2(ξ,y
(j)
mis | H).
Here, y
(j)
mis can be a fraction. Under standard regularity conditions, the sequence
{p(j), ξ(j), j = 1, 2, . . .} converges to arg maxp,ξ L(p, ξ | H).
Appendix D. Design Properties
D.1. Large-Sample Convergence Properties.
Proof of Lemma 5.1. (1) In the likelihood (3.2), we first treat ξ as a fixed parameter.
Conditional on ξ, pz is independent of the information at the other doses, which
simplifies the problem. In the end, we will integrate out ξ and show the lemma also
holds unconditional on ξ. For notation simplicity, we suppress the subscript z in the
following proof and only consider the patients at dose z. That is, Nz, nz, mz, rz, pz
and p0z are simplified as N , n, m, r, p and p0. Also, yi, y˜i, vi and bi now only refer
to the DLT outcome, current toxicity status, follow-up time and observed outcome
indicator for a patient i at dose z, i = 1, . . . , Nz. Without loss of generality, assume
0 < p0 −  < p0 < p0 +  < 1, thus log(p0 − ), log p0 and log(1 − p0 − ) are finite.
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The likelihood of p is
L(p | H, ξ) =
N∏
i=1
{
p1(y˜i=1)(1− p)1(y˜i=0,vi=W ) [1− ρ(vi | z, ξ)p]1(y˜i=0,vi<W )
}
=
N∏
i=1
{
p1(yi=1,bi=0)(1− p)1(yi=0,bi=0) [1− ρ(vi | z, ξ)p]1(bi=1)
}
.
Define
ηN(p;H, ξ) = 1
N
log
L(p0 | H, ξ)
L(p | H, ξ) .(D.1)
We have
ηN(p;H, ξ) = 1
N
{
n(log p0 − log p) +m[log(1− p0)− log(1− p)]+∑
i:bi=1
[log(1− ρip0)− log(1− ρip)]
}
,
where ρi = ρ(vi | z, ξ), and 0 ≤ ρi ≤ 1. Thus,
η
N
(p;H) ≤ ηN(p;H, ξ) ≤ ηN(p;H),
where
η
N
(p;H) = 1
N
[n(log p0 − log p) + (m+ r) log(1− p0)−m log(1− p)] ,
ηN(p;H) =
1
N
[n(log p0 − log p) +m log(1− p0)− (m+ r) log(1− p)] .
By taking derivatives, we know η
N
(p;H) monotonically decreases on [0, n/(n+m)),
reaches the minimum at n/(n + m) and monotonically increases on (n/(n + m), 1];
ηN(p;H) monotonically decreases on [0, n/N), reaches the minimum at n/N and
monotonically increases on (n/N, 1]
Furthermore, let
η∗(p) = p0(log p0 − log p) + (1− p0)[log(1− p0)− log(1− p)].
Similarly, η∗(p) monotonically decreases on [0, p0), reaches the minimum at p0 and
monotonically increases on (p0, 1]. We have η
∗(p0) = 0. Since η∗(p) is continuous,
∃δ > 0 and 0 < 0 < , such that min{η∗(p0 − ), η∗(p0 + )} > 5δ and max{η∗(p0 −
0), η
∗(p0 + 0)} < δ.
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Let C¯ε denote the complement of Cε. Recall that Cε = {p : |p− p0| < ε}. Consider
the posterior odds,∫
Cε pi(p | H, ξ)dp∫
C¯ε pi(p | H, ξ)dp
=
∫
Cε pi0(p)L(p | H, ξ)dp∫
C¯ε pi0(p)L(p | H, ξ)dp
=
∫
Cε pi0(p) exp[−NηN(p;H, ξ)]dp∫
C¯ε pi0(p) exp[−NηN(p;H, ξ)]dp
.(D.2)
According to the strong law of large numbers, and since r = o(N), ∃N0 (note that
N0 does not depend on ξ), ∀N > N0,
max
{∣∣∣∣ nn+m − p0
∣∣∣∣ , ∣∣∣ nN − p0∣∣∣ ,
∣∣∣∣n+ rN − p0
∣∣∣∣} <
min
{
0,
1
4
∣∣∣∣ δlog(p0 − )
∣∣∣∣ , 14
∣∣∣∣ δlog(1− p0 − )
∣∣∣∣} ,
almost surely (a.s.). We have
|η
N
(p0 − ;H)− η∗(p0 − )| ≤
∣∣∣ n
N
− p0
∣∣∣ · |log p0|+ ∣∣∣ n
N
− p0
∣∣∣ · |log(p0 − )|+∣∣∣ n
N
− p0
∣∣∣ · |log(1− p0)|+ ∣∣∣∣n+ rN − p0
∣∣∣∣ · |log(1− p0 + )| ≤ δ.
Thus, for all p ≤ p0 − ,
ηN(p;H, ξ) ≥ ηN(p;H) ≥ ηN(p0 − ;H)
≥ η∗(p0 − )− |ηN(p0 − ;H)− η∗(p0 − )| > 4δ.
Similarly, for all p ≥ p0 + , we have ηN(p;H, ξ) > 4δ.
Next, consider p0 − 0 ≤ p ≤ p0 + 0. We have
|ηN(p0 − 0;H)− η∗(p0 − 0)| ≤
∣∣∣ n
N
− p0
∣∣∣ · |log p0|+ ∣∣∣ n
N
− p0
∣∣∣ · |log(p0 − 0)|+∣∣∣∣n+ rN − p0
∣∣∣∣ · |log(1− p0)|+ ∣∣∣ nN − p0∣∣∣ · |log(1− p0 + 0)| ≤ δ.
Thus, for all p0 − 0 ≤ p ≤ n/N ,
ηN(p;H, ξ) ≤ ηN(p;H) ≤ ηN(p0 − 0;H)
≤ η∗(p0 − 0) + |ηN(p0 − 0;H)− η∗(p0 − 0)| < 2δ.
Similarly, for all n/N ≤ p ≤ p0 + 0, we have ηN(p;H, ξ) < 2δ.
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As a result, in Equation (D.2), the numerator and the denominator satisfy∫
Cε
pi0(p) exp[−NηN(p;H, ξ)]dp ≥ exp(−2Nδ)pi0(p ∈ C0),∫
C¯ε
pi0(p) exp[−NηN(p;H, ξ)]dp ≤ exp(−4Nδ),
respectively, for all N > N0 a.s. That is, for some δ > 0 and 0 < 0 < , ∃N0 > 0,
∀N > N0, (D.2) ≥ exp(2Nδ)pi0(p ∈ C0) a.s.
Since the numerator and the denominator of (D.2) add up to 1, through simple
algebra we have pi(p ∈ Cε | H, ξ) ≥ 1− [1+exp(2Nδ)pi0(p ∈ C0)]−1. Notice that none
of the terms on the right hand side depend on ξ. Thus,
pi(p ∈ Cε | H) =
∫
ξ
pi(p ∈ Cε | H, ξ)pi(ξ | H)dξ
≥
∫
ξ
{
1− [1 + exp(2Nδ)pi0(p ∈ C0)]−1
}
pi(ξ | H)dξ
= 1− [1 + exp(2Nδ)pi0(p ∈ C0)]−1
and goes to 1 a.s. as N →∞.
(2) In (1) we have already proved ∀ > 0, ∃N0, ∀N > N0, ∃δ > 0 such that
ηN(p;H, ξ) > 4δ for all p ∈ C¯ε and for all ξ a.s. Since the log-likelihood at the
MLE pˆ must be greater than or equal to the log-likelihood at any other place (includ-
ing p0), we have ηN(pˆ;H, ξˆ) ≤ 0. As a result, pˆ ∈ C¯ε would cause a contradiction.
Therefore, ∀ > 0, ∃N0, ∀N > N0, pˆ ∈ Cε a.s., which means pˆ→ p0. 
Proof of Theorem 5.1. The proof follows Oron et al. (2011) as a consequence of
Lemma 5.1. Define the random set
Z = {z ∈ {1, . . . , D} : Nz →∞ as N →∞},
where Nz is the number of patients assigned to dose z. Obviously, Z is nonempty
and is composed of consecutive dose levels, Z = {Z1, . . . , Z2}. Here Z1, . . . , Z2 are
consecutively ordered integers (Z1 ≤ Z2). For a particular dose d∗, the possible
configurations of Z can be partitioned into three subspaces: A = {Z1 = Z2 = d∗},
B = {Z1 < Z2 and d∗ ∈ Z} and C = {d∗ /∈ Z}. Almost sure convergence to d∗ is
equivalent to Pr(A) = 1.
Suppose the dose d∗ satisfies p0d∗ ∈ (pT − 1, pT + 2), and d∗ is also the only
dose such that p0d∗ ∈ [pT − 1, pT + 2]. We first prove Pr(C) = 0 by contradiction.
With out loss of generality, we assume there is some specific dose z1 > d
∗ for which
Pr(Z1 = z1) > 0. From the theorem’s condition, p0z1 > pT + 2. When the event
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Z1 = z1 happens, Nz1 → ∞ as N → ∞. Thus ∀ > 0, for N large enough, pi[pz1 ∈
(p0z1 − , p0z1 + ) | H] → 1, meaning arg maxj Pr(pz1 ∈ Ij | H) ∈ {O1, . . . ,OK2}.
Similarly, for N large enough, the MLE pˆz1 > pT + 2. According to the transition
rule of interval-based designs, the next lower dose level z1 − 1 will be assigned a.s.
following each allocation to z1. Thus z1 − 1 ∈ Z, reaching a contradiction. As a
result, for all z1 > d
∗, Pr(Z1 = z1) = 0. Based on similar reasoning, for all z2 < d∗,
Pr(Z2 = z2) = 0. This means with probability 1, Z1 ≤ d∗ and Z2 ≥ d∗, i.e., d∗ ∈ Z.
Since d∗ ∈ Z, Nd∗ → ∞ as N → ∞. Thus ∀ > 0, for N large enough, pi[pd∗ ∈
(p0d∗ − , p0d∗ + ) | H] → 1, meaning Pr(pd∗ ∈ IE | H) → 1. Similarly, for N large
enough, the MLE pˆd∗ ∈ IE. According to the transition rule of interval-based designs,
the same dose level d∗ will be retained a.s. following each assignment to d∗. Thus,
there is no other level in Z with probability 1, and the dose allocation converges a.s.
to d∗. 
Proof of Lemma 5.2. For notation simplicity, we suppress the subscript d in the fol-
lowing proof and only consider the patients with Zi = d, as interval-based nonpara-
metric designs (defined in Section 2) only use information at the current dose. Sup-
pose A∗(y) is the dose decision function of an interval-based nonparametric complete-
data design, where y denotes the vector of outcomes at the current dose only. We
have
Pr(A = a | H) =
∑
ymis:A∗(yobs,ymis)=a
Pr(Ymis = ymis | H).
Again, yobs and Ymis now only refer to the observed outcomes and unknown outcomes
for patients at the current dose. Let Ymis = {0, 1}r denote the support of Ymis, where
r is the number of pending patients at the current dose.
(1) Suppose p0 ∈ (pT − 1, pT + 2). It suffices to show ∀ymis ∈ Ymis, ∃N0 > 0,
when N > N0, A∗(yobs,ymis) = d a.s. For a complete-data design with outcomes
(yobs,ymis), the likelihood of p is
L(p | yobs,ymis) =
N∏
i=1
pyi(1− p)1−yi = pn+s(1− p)m+r−s,
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where s =
∑r
l=1 1(ymis,l = 1) counts the number of DLTs in ymis, 0 ≤ s ≤ r. Similar
to Equation (D.1), consider
ηN(p;yobs,ymis) =
1
N
log
L(p0 | yobs,ymis)
L(p | yobs,ymis)
=
1
N
{
(n+ s)(log p0 − log p) + (m+ r + s)[log(1− p0)− log(1− p)]
}
.
The function ηN(p;yobs,ymis) monotonically decreases on [0, (n+ s)/N), reaches the
minimum at (n+ s)/N and monotonically increases on ((n+ s)/N, 1].
Let 0 = min{1, 2}. Similar to the proof of Lemma 5.1, by the strong law of large
numbers, and since r = o(N), we can show ∃N0 > 0, when N > N0, pi(p ∈ C0 |
yobs,ymis) ≥ 0.99 a.s., for any 0 ≤ s ≤ r. Also, when N > N0, |pˆ − p0| < 0 a.s.
If p0 ∈ (pT − 1, pT + 2), then for N > N0 and for any ymis, arg maxj Pr(p ∈ Ij |
yobs,ymis) = E and pˆ ∈ IE a.s. That is, A∗(yobs,ymis) = d for any ymis. As a result,
Pr(A = d | H) =
∑
ymis∈Ymis
Pr(Ymis = ymis | H) = 1,
a.s. for N > N0.
(2, 3) For the same reason, if p0 < pT − 1, then ∃N0, when N > N0, ∀ymis ∈ Ymis,
A∗(yobs,ymis) = d+ 1 a.s. Thus Pr(A = d+ 1 | H) = 1 a.s. If p0 > pT + 2, then ∃N0,
when N > N0, ∀ymis ∈ Ymis, A∗(yobs,ymis) = d− 1 a.s. Thus Pr(A = d− 1 | H) = 1
a.s. 
D.2. Coherence Principles. We prove below for a simple case that an interval-
based TITE design is interval coherent in the sense of Definition 5.2.
Consider an interval-based TITE design that makes dose-finding decisions based
on the MLE (see Section 2). We establish its interval coherence in de-escalation.
First, consider a function
`(p, ρ1, . . . , ρr;n,m) ,
n
p
− m
1− p −
r∑
i=1
ρi
1− ρip,
where n, m and r are some non-negative integers. We have
∂`
∂p
= − n
p2
− m
(1− p)2 −
r∑
i=1
ρ2i
(1− ρip)2 < 0, and
∂`
∂ρi
= − 1
(1− ρip)2 < 0,
for all p and ρi, which mean that ` monotonically decreases with p and ρi.
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Next, suppose the currently-administrated doses just prior to τ and τ +τ ′ are both
d. At dose d, let nd and md denote the numbers patients that have or do not have
DLTs just prior to τ , let i = 1, . . . , r1 index the patients that are still being followed
just prior to τ , and let i = r1 + 1, . . . , r2 index the patients that are enrolled between
[τ, τ + τ ′). The MLE of pd just prior to τ , denoted by pˆd(τ), satisfies
`[pˆd(τ), ρ1(τ), . . . , ρr1+r2(τ);nd,md] = 0,
where ρi(τ) = ρ[vi(τ) | d, ξˆ] for some ξˆ for i = 1, . . . , r1, and ρi(τ) = 0 for i =
r1 +1, . . . , r2. On the other hand, suppose no DLT occurs at dose d during [τ, τ + τ
′).
Then, the MLE of pd just prior to τ + τ
′, denoted by pˆd(τ + τ ′), satisfies
`[pˆd(τ + τ
′), ρ1(τ + τ ′), . . . , ρr1+r2(τ + τ
′);nd,md] = 0,
where ρi(τ + τ
′) = ρ[vi(τ + τ ′) | d, ξˆ] if patient i is still being followed just prior to
τ + τ ′, and ρi(τ + τ ′) = 1 if patient i has finished followup just prior to τ + τ ′ with
no DLT.
By definition, ρi(τ + τ
′) ≥ ρi(τ). Therefore,
`[pˆd(τ + τ
′), ρ1(τ), . . . , ρr1+r2(τ);nd,md] ≥
`[pˆd(τ + τ
′), ρ1(τ + τ ′), . . . , ρr1+r2(τ + τ
′);nd,md] = 0 =
`[pˆd(τ), ρ1(τ), . . . , ρr1+r2(τ);nd,md].
Since `monotonically decreases with p, we have pˆd(τ+τ
′) ≤ pˆd(τ), thusA[H(τ+τ ′)] ≥
A[H(τ)]. Coherence in escalation can be proved in a similar way.
Appendix E. Selection of the MTD
Except for the 3+3 and R6 designs, the patient enrollment is terminated if the
number of enrolled patients reaches the pre-specified maximum sample size N∗ or an
early stopping rule (e.g. Safety rule 1) is triggered. After all patients have finished
their DLT assessment, the trial completes, and the next step is to recommend an
MTD. The selection of MTD does not involve any pending outcomes and is simply
a problem of statistical inference about p under the likelihood (2.2) and the order
constraint p1 ≤ p2 ≤ · · · ≤ pD. Usually, the doses with Pr(pz > pT | data) > ν for
a ν close to 1 and the doses that have never been tried are excluded from the MTD
candidates. If the trial is stopped early because the lowest dose is overly toxic, no
MTD will be selected.
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The MTD selection rules for the CRM and SPM are consistent with their dose
assignment rules. For CRM, the dose d∗ = arg minz |pˆz− pT| is selected as the MTD.
For SPM, the dose γˆ = arg maxγ pi(γ | y, z) is selected as the MTD. See more details
in Sections A.1 and A.5. On the other hand, the MTD selection rules for the BOIN,
mTPI-2, keyboard and i3+3 are different from their dose assignment rules, as their
dose assignments only depend on outcomes at the current dose. To impose the order
constraint, an isotonic regression is performed using the pooled adjacent violators
algorithm (Ji et al., 2007), resulting in estimates pˆ satisfying pˆ1 ≤ pˆ2 ≤ · · · ≤ pˆD.
For BOIN and keyboard, the dose d∗ = arg minz |pˆz − pT| is selected as the MTD.
For mTPI-2 and i3+3, the dose d∗ with the smallest distance will be selected only
if pˆd∗ ≤ pT + 2, and otherwise, the highest dose with DLT probability lower than
pT + 2 is selected, which is more conservative. For the time-to-event designs, we can
simply apply the MTD selection rules of their complete-data counterparts.
Appendix F. Simulation Details
F.1. Dose-Toxicity Scenarios. We summarize the 18 dose-toxicity scenarios in
Table F.1. We follow Guo et al. (2017) to define the MTD as the highest dose
whose probability of DLT is close to or lower than pT. Specifically, the doses z with
pz ∈ [pT − 0.05, pT + 0.05] are considered MTDs, and if such doses do not exist, the
highest dose z with pz < pT is considered as the MTD. We note the definition of
MTD may be slightly different in other articles.
F.2. Design Specifications. We first provide a brief review of the R-TPI design
(Guo et al., 2019). R-TPI is an extension to the mTPI-2 design. Suppose the current
dose is d. R-TPI allows dose escalation only in the case that even all the rd pending
outcomes are toxic, the mTPI-2 decision is still escalation. In other cases, the R-TPI
decision is stay or de-escalation, based on conservative guess of Ymis. R-TPI does not
utilize time-to-event information, although it is among the safest designs that allow
pending outcomes.
For all the designs, we start from the lowest dose. The specification of each design
is as follows. For TITE-CRM, we use the power model, pz = φ(z, α) = p
exp(α)
0z ,
with α ∼ N(0, 1.342). The skeleton (p01, . . . , p0D) is calibrated based on Lee and
Cheung (2009), with prior guess of MTD being the middle dose 4 and halfwidth
of the indifference interval being 0.05. A uniform distribution is assumed for [T |
Z, Y = 1]. For TITE-TPI, POD-TPI, mTPI-2 and R-TPI, the equivalence interval
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Table F.1. True DLT probabilities of the 18 dose-toxicity scenarios.
The target DLT probability is 0.2 for scenarios 1–9 and is 0.3 for sce-
narios 10–18. The MTDs are marked in bold.
Scn.
Dose levels
1 2 3 4 5 6 7
Target DLT probability 0.20
1 0.28 0.36 0.44 0.52 0.60 0.68 0.76
2 0.05 0.20 0.46 0.50 0.60 0.70 0.80
3 0.02 0.05 0.20 0.28 0.34 0.40 0.44
4 0.01 0.05 0.10 0.20 0.32 0.50 0.70
5 0.01 0.04 0.07 0.10 0.50 0.70 0.90
6 0.01 0.05 0.10 0.14 0.20 0.26 0.34
7 0.01 0.02 0.03 0.05 0.20 0.40 0.50
8 0.01 0.04 0.07 0.10 0.15 0.20 0.25
9 0.01 0.02 0.03 0.04 0.05 0.20 0.45
Target DLT probability 0.30
10 0.40 0.45 0.50 0.55 0.60 0.65 0.70
11 0.30 0.40 0.50 0.60 0.70 0.80 0.90
12 0.14 0.30 0.39 0.48 0.56 0.64 0.70
13 0.07 0.23 0.41 0.49 0.62 0.68 0.73
14 0.05 0.15 0.30 0.40 0.50 0.60 0.70
15 0.05 0.12 0.20 0.30 0.38 0.49 0.56
16 0.01 0.04 0.08 0.15 0.30 0.36 0.43
17 0.02 0.04 0.08 0.10 0.20 0.30 0.40
18 0.01 0.03 0.05 0.07 0.09 0.30 0.50
is chosen with 1 = 2 = 0.05. For TITE-TPI and POD-TPI, a piecewise uniform
distribution is assumed for [T | Z, Y = 1] with 3 equal-length sub-intervals. A
Dir(1, 1, 1) prior is assumed for the sub-interval weights (ω1, ω2, ω3). For TITE-BOIN,
the decision boundaries are calculated based on pL = 0.6pT and pR = 1.4pT. A
uniform distribution is assumed for [T | Z, Y = 1].
The MTD selection rules of the time-to-event designs follow their complete-data
counterparts. The doses with Pr(pz > pT | data) > 0.95 are excluded from the MTD
candidates for all designs.
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F.3. Scenario-specific Results. Figures F.1, F.2 and F.3 show the scenario-specific
operating characteristics for mTPI-2, R-TPI, TITE-TPI, POD-TPI, TITE-CRM and
TITE-BOIN under Setting 1.
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Figure F.1. Scenario-specific PCS, PCA and POS for mTPI-2, R-
TPI, TITE-TPI, POD-TPI, TITE-CRM and TITE-BOIN under Set-
ting 1.
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Figure F.2. Scenario-specific POA, POT and Dur for mTPI-2, R-
TPI, TITE-TPI, POD-TPI, TITE-CRM and TITE-BOIN under Set-
ting 1.
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Figure F.3. Scenario-specific frequencies of incompatible and risky
decisions (DS, DE and SE) for mTPI-2, R-TPI, TITE-TPI, POD-TPI,
TITE-CRM and TITE-BOIN under Setting 1.
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F.4. Time-to-Toxicity Model Specifications. To explore the role of the time-
to-toxicity model, we run additional simulations with the following five models: (1)
uniform distribution; (2) piecewise uniform distribution with 3 sub-intervals; (3)
piecewise uniform distribution with 9 sub-intervals; (4) discrete hazard model; and
(5) piecewise constant hazard model with 3 sub-intervals. For model (2), we consider
3 equal-length sub-intervals, hk = kW/K for K = 3. A Dir(1, 1, 1) prior is assumed
for the sub-interval weights (ω1, ω2, ω3) (see Section B.2). For model (3), we consider
9 equal-length sub-intervals, hk = kW/K for K = 9. A Dir(1, . . . , 1) prior is assumed
for the sub-interval weights (ω1, . . . , ω9). For model (4), we assume a Beta(0.5, 0.5)
prior for ωk, which is the discrete hazard at time hk (see Section B.3). For model
(5), we consider 3 equal-length sub-intervals, hk = kW/K for K = 3. We follow Liu
et al. (2013) and assume a Gamma(K/[2W (K − k+ 0.5)], 1/2) prior for ωk, which is
the hazard in the kth sub-interval (see Section B.4).
